Search

Your search keyword '"MESH : Young Adult"' showing total 171 results
Start Over Descriptor "MESH : Young Adult"
171 results on '"MESH : Young Adult"'

1. Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?

Author

Alain Monnereau, Sébastien Orazio, Olivier Dejardin, Sandra Le Guyader-Peyrou, Marc Maynadié, Xavier Troussard, Registre des hémopathies malignes de la Gironde, Institut Bergonié - CRLCC Bordeaux, Cancer environnement ( EPICENE ), Bordeaux population health ( BPH ), Université de Bordeaux ( UB ) -Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Bordeaux ( UB ) -Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Cancers et préventions, Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Registre des hémopathies malignes de Côte d'Or, Registre des hémopathies malignes de Basse-Normandie, CHU Caen, Laboratoire d'hématologie biologique [Caen], Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, Cancer environnement (EPICENE ), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Registre des hémopathies malignes de Basse-Normandie [CHU Caen], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Laboratoire d'Hématologie Biologique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), université de Bourgogne, LNC, and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, 0301 basic medicine, Pediatrics, Multivariate analysis, MESH: Registries, MESH : Aged, MESH: Comorbidity, Comorbidity, MESH : Lymphoma, Large B-Cell, Diffuse, MESH: Aged, 80 and over, 0302 clinical medicine, International Prognostic Index, MESH : Child, MESH: Child, MESH : Population Surveillance, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, MESH : Female, Registries, Young adult, Child, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Relative survival, MESH: Patient Outcome Assessment, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Articles, Hematology, Middle Aged, MESH : Adult, Prognosis, MESH : Patient Outcome Assessment, 3. Good health, MESH: Young Adult, Population Surveillance, MESH: Survival Analysis, 030220 oncology & carcinogenesis, MESH : Comorbidity, Marital status, Female, France, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin Leukemia, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH: Factor Analysis, Statistical, MESH : Young Adult, MESH : Factor Analysis, Statistical, MESH: Prognosis, MESH: Population Surveillance, MESH: Social Class, Young Adult, 03 medical and health sciences, MESH : Adolescent, Internal medicine, MESH : Social Class, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH : France, Survival analysis, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, medicine.disease, Survival Analysis, MESH: Male, Patient Outcome Assessment, MESH: France, 030104 developmental biology, Social Class, MESH: Lymphoma, Large B-Cell, Diffuse, MESH : Survival Analysis, Factor Analysis, Statistical, business, MESH: Female, Diffuse large B-cell lymphoma, MESH : Registries
Abstract

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were performed and missing data were controlled with the multiple imputation method. In a multivariate analysis, adjusted for age, sex and International Prognostic Index, we confirmed that time period was associated with a better 5-year relative survival. The registry area, the medical specialty of the care department (onco-hematology versus other), the time to travel to the nearest teaching hospital, the place of treatment (teaching versus not-teaching hospital -borderline significance), a comorbidity burden and marital status were independently associated with the 5-year relative survival. Adjusted for first-course treatment, inclusion in a clinical trial and treatment discussion in a multidisciplinary meeting were strongly associated with a better survival outcome. In contrast, socio-economic status (determined using the European Deprivation Index) was not associated with outcome. Despite therapeutic advances, various non-biological factors affected the relative survival of patients with diffuse large B-cell lymphoma. The notion of lymphoma-specific expertise seems to be essential to achieve optimal care management and reopens the debate regarding centralization of these patients' care in hematology/oncology departments.

Published
2016

2. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients

Author

Raphaël Chiron, Laurent Debarbieux, Frédérique Carrié, Nicolas Molinari, Isabelle Sermet, Isabelle Vachier, Jean-Paul Pirnay, Emilie Saussereau, Nicolas Dufour, Benoit Godbert, Daniel De Vos, Debarbieux, Laurent, Cellule Pasteur UPMC, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris] (IP), Biologie Moléculaire du Gène chez les Extrêmophiles (BMGE), Institut Pasteur [Paris] (IP), Département des Maladies Respiratoires [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Service de Pneumologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche Croissance et signalisation (UMR_S 845), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cellule Pasteur, Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité, Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital [Brussels], PHAGESPOIRS, Mathématiques, Informatique et STatistique pour l'Environnement et l'Agronomie (MISTEA), Institut National de la Recherche Agronomique (INRA)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), This work was supported by Vaincre la Mucoviscidose, the French Cystic Fibrosis Foundation [RC20120600714/1/1/141], and Programme Transversal de Recherches [417] from Institut Pasteur and Assistance Publique Hôpitaux de Paris., Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris], Institut Pasteur [Paris], Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de la Recherche Agronomique (INRA), PRES Sorbonne Paris Cité-Université Paris Diderot - Paris 7 (UPD7), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Institut National de la Recherche Agronomique (INRA), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut Pasteur [Paris], Biologie Moléculaire du Gène chez les Extrêmophiles ( BMGE ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre de recherche Croissance et signalisation ( UMR_S 845 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Diderot - Paris 7 ( UPD7 ) -PRES Sorbonne Paris Cité, Mathématiques, Informatique et STatistique pour l'Environnement et l'Agronomie ( MISTEA ), and Institut National de la Recherche Agronomique ( INRA ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro )

Subjects
Male, Time Factors, Cystic Fibrosis, medicine.medical_treatment, Antibiotics, pulmonary infection, [ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, medicine.disease_cause, MESH: Bacterial Load, Cystic fibrosis, MESH : Cross-Sectional Studies, MESH: Sputum, MESH : Female, MESH: Microbial Viability, MESH: Middle Aged, biology, MESH: Pseudomonas Infections, General Medicine, MESH : Adult, MESH : Pseudomonas aeruginosa, Middle Aged, MESH : Pseudomonas Infections, 3. Good health, Biological Therapy, Chronic infection, medicine.anatomical_structure, Infectious Diseases, MESH: Young Adult, Pseudomonas aeruginosa, MESH: Pseudomonas aeruginosa, Female, MESH : Bacterial Load, medicine.symptom, Pseudomonas Phages, MESH : Time Factors, Adult, Microbiology (medical), phage therapy, Phage therapy, Adolescent, MESH: Cystic Fibrosis, medicine.drug_class, MESH : Male, MESH : Young Adult, MESH: Pseudomonas Phages, Microbiology, Young Adult, MESH: Cross-Sectional Studies, MESH : Adolescent, MESH : Cystic Fibrosis, medicine, Humans, MESH : Middle Aged, Pseudomonas Infections, MESH: Adolescent, Microbial Viability, MESH: Humans, MESH : Humans, MESH: Time Factors, MESH : Microbial Viability, Sputum, MESH: Adult, medicine.disease, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Bacterial Load, MESH: Male, Cross-Sectional Studies, MESH : Pseudomonas Phages, MESH : Sputum, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Biological Therapy, MESH: Female, MESH : Biological Therapy, Bacteria, Respiratory tract
Abstract

International audience; Bacteriophages have been shown to be effective for treating acute infections of the respiratory tract caused by antibiotic-resistant bacteria in animal models, but no evidence has yet been presented of their activity against pathogens in complex biological samples from chronically infected patients. We assessed the efficacy of a cocktail of ten bacteriophages infecting Pseudomonas aeruginosa following its addition to 58 sputum samples from cystic fibrosis (CF) patients collected at three different hospitals. Ten samples that did not contain P. aeruginosa were not analysed further. In the remaining 48 samples, the addition of bacteriophages led to a significant decrease in the levels of P. aeruginosa strains, as shown by comparison with controls, taking two variables (time and bacteriophages) into account (p = 0.024). In 45.8% of these samples, this decrease was accompanied by an increase in the number of bacteriophages. We also tested each of the ten bacteriophages individually against 20 colonies from each of these 48 samples and detected bacteriophage-susceptible bacteria in 64.6% of the samples. An analysis of the clinical data revealed no correlation between patient age, sex, duration of P. aeruginosa colonization, antibiotic treatment, FEV1 (forced expiratory volume in the first second) and the efficacy of bacteriophages. The demonstration that bacteriophages infect their bacterial hosts in the sputum environment, regardless of the clinical characteristics of the patients, represents a major step towards the development of bacteriophage therapy to treat chronic lung infections.

Published
2014
Full Text
View/download PDF

3. Impact of body composition on outcome in patients with early breast cancer

Author

Elise Deluche, Julie Usseglio, Sophie Leobon, Nicole Tubiana-Mathieu, Laurence Venat-Bouvet, Jean Claude Desport, Grelier, Elisabeth, Service d'Oncologie médicale [CHU Limoges], CHU Limoges, and Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges]

Subjects
Sarcopenia, Multivariate analysis, MESH : Retrospective Studies, MESH : Aged, Adipose tissue, MESH : Breast Neoplasms, Body composition, 0302 clinical medicine, MESH : Female, 030212 general & internal medicine, Early breast cancer, Aged, 80 and over, MESH : Prognosis, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, Middle Aged, Prognosis, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH : Disease-Free Survival, Female, Original Article, Adult, medicine.medical_specialty, MESH : Body Composition, Urology, MESH : Young Adult, Breast Neoplasms, Disease-Free Survival, 03 medical and health sciences, Young Adult, Breast cancer, medicine, Humans, In patient, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, Retrospective Studies, business.industry, MESH : Humans, Skeletal muscle, Retrospective cohort study, medicine.disease, Surgery, MESH : Sarcopenia, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

International audience; PURPOSE:We investigated the impact of body composition on outcomes of patients with early breast cancer. Skeletal muscle mass, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and muscle fat infiltration or inter-muscular adipose tissue areas (IMAT), obtained by computed tomography (CT), were assessed.METHODS:A total of 119 female patients who had breast cancer were included in this retrospective study. The total skeletal muscle and fat tissue areas were evaluated in two adjacent axial slices obtained at the third lumbar vertebra by CT used for disease staging. The women were assigned to either a sarcopenia or non-sarcopenia group based on their skeletal muscle index (cut-off 41.0 cm2/m2). They also were classified into high and low VAT/SAT ratio groups and assigned to either the high or low IMAT index group. The association of the body composition parameters and prognosis was statistically analyzed.RESULTS:Among the 119 evaluable patients, 58 were sarcopenic (48.8%), 55 (46.2%) had a high VAT/SAT ratio, and 62 (52.1%) had a high IMAT index. Median follow-up was 52.4 months. Multivariate analysis revealed sarcopenia and IMAT index as independent prognostic factors for disease-free survival (p = 0.02 and p = 0.04, respectively) and overall survival (p = 0.05 and p = 0.02, respectively). BMI was not significantly associated with disease-free survival, but a trend was observed (p = 0.09).CONCLUSIONS:Sarcopenia and IMAT index are independent prognostic factors in early breast cancer; therefore, assessing body composition could be a simple and useful approach to integrate into patient management.

Published
2017

4. Fungal peptides from pneumonitis hypersensitivity etiologic agents are able to induce specific cellular immune response

Author

Anne-Pauline Bellanger, Laurence Millon, Bénédicte Rognon, Houssein Gbaguidi-Haore, Thibaud Lignon, Christophe Borg, Gabriel Reboux, Yann Godet, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), Service de parasitologie et mycologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d’Hygiène Hospitalière, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université de Franche-Comté ( UFC ), Service de parasitologie et mycologie [CHU de Besançon], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), and Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC )

Subjects
Male, MESH : Aged, Epitope, MESH : Antigens, Fungal, Epitopes, 0302 clinical medicine, MESH: Peptide Fragments, Cells, Cultured, MESH: Middle Aged, ELISPOT, Acquired immune system, Healthy Volunteers, 3. Good health, MESH : Mucorales, MESH: Young Adult, Mucorales, MESH: Mucorales, MESH: Cells, Cultured, Antigens, Fungal, MESH: Epitopes, MESH : Dihydrolipoamide Dehydrogenase, T cell, MESH : Alveolitis, Extrinsic Allergic, Immunology, MESH : Young Adult, MESH : Epitopes, Statistics, Nonparametric, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, Interferon-gamma, 03 medical and health sciences, MESH: Mycobacterium, Humans, MESH : Middle Aged, Aged, Dihydrolipoamide Dehydrogenase, MESH: Antigens, Fungal, MESH: Humans, Histocompatibility Antigens Class I, MESH : Humans, Histocompatibility Antigens Class II, MESH: Adult, Peptide Fragments, MESH : Leukocytes, Mononuclear, 030104 developmental biology, Leukocytes, Mononuclear, MESH: Female, 0301 basic medicine, Enzyme-Linked Immunospot Assay, MESH : Enzyme-Linked Immunospot Assay, MESH: Histocompatibility Antigens Class I, ELISPOT assay, Immunology and Allergy, MESH : Female, Interferon gamma, MESH: Healthy Volunteers, MESH: Aged, Immunity, Cellular, MESH: Statistics, Nonparametric, biology, MESH : Antigens, Bacterial, Middle Aged, MESH : Adult, MESH: Leukocytes, Mononuclear, MESH : Histocompatibility Antigens Class II, medicine.anatomical_structure, Female, MESH : Histocompatibility Antigens Class I, Alveolitis, Extrinsic Allergic, medicine.drug, Adult, MESH: Dihydrolipoamide Dehydrogenase, MESH: Interferon-gamma, MESH : Male, MESH: Alveolitis, Extrinsic Allergic, Major histocompatibility complex, Mycobacterium, MESH: Immunity, Cellular, Young Adult, Immune system, MESH : Cells, Cultured, medicine, MESH : Mycobacterium, MESH : Statistics, Nonparametric, MESH : Interferon-gamma, MESH : Healthy Volunteers, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, Antigens, Bacterial, MESH: Epitope Mapping, MESH : Peptide Fragments, MESH : Immunity, Cellular, biology.organism_classification, MESH: Male, MESH : Epitope Mapping, biology.protein, MESH: Histocompatibility Antigens Class II, Mycobacterium immunogenum, MESH: Enzyme-Linked Immunospot Assay, Epitope Mapping, Hypersensitivity pneumonitis, MESH: Antigens, Bacterial, 030215 immunology, IFNγ
Abstract

International audience; Hypersensitivity pneumonitis (HP) is an immunoallergic disease due to chronic exposure to high quantities of different microorganisms such as Mycobacterium immunogenum (Mi), a mycobacterium, and Lichtheimia corymbifera (Lc), a filamentous fungus. It has recently been demonstrated that the protein DLDH (dihydrolipoyl dehydrogenase), is common to these microorganisms. This study aimed to investigate the immune potential of overlapping peptide pools covering the MiDLDH and LcDLDH.; A selection of 34 peptides, from the MiDLDH and LcDLDH, able to interact with Major Histocompatibility Complex (MHC) 1 and MHC 2, was obtained using three different epitope prediction websites. By means of ELISPOT assays, we compared the frequency of Interferon gamma (IFNγ) secreting peripheral blood mononuclear cells (PBMC) after stimulation with overlapping peptide pools. Tests were performed using cells from 35 healthy blood donors.; One peptide pool containing five peptides from MiDLDH and able to interact with MHC 2 induced a marked IFNγ specific immune response (Pool F, p

Published
2017

5. Pathologies neurologiques en milieu tropical et rural : expérience malgache d’un centre de santé primaire de la région de Boeny

Author

S. Gaud, M. Sauvée, Marc Debouverie, Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), and Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL)

Subjects
Male, Rural Population, Neurology, Primary health care, soins de santé primaires, MESH: Madagascar, Epilepsy, MESH: Rural Population, Health care, MESH : Female, MESH : Primary Health Care, neurologie, 1. No poverty, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, épilepsie, 3. Good health, MESH : Tropical Climate, Infectious Diseases, MESH: Young Adult, MESH: Tropical Climate, Female, Headaches, medicine.symptom, leprosy, Adult, medicine.medical_specialty, MESH : Madagascar, MESH : Male, MESH : Young Adult, Developing country, MESH: Nervous System Diseases, MESH: Primary Health Care, Young Adult, primary healthcare, Primary headache, Primary health, Madagascar, medicine, Humans, Tropical Climate, MESH: Humans, Primary Health Care, business.industry, neurology, MESH : Humans, Public Health, Environmental and Occupational Health, MESH: Adult, MESH : Nervous System Diseases, medicine.disease, MESH: Male, MESH : Rural Population, lèpre, Family medicine, epilepsy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Nervous System Diseases, business, MESH: Female
Abstract

International audience; There is, to our knowledge, no study reporting the demand for health care related to neurological diseases in rural tropical areas of developing countries. Neurology is nonetheless more or less closely related to the priority health issues in these countries. Over a 6-week period, 626 patients were seen at the primary health center in the town of Madirovalo, Madagascar. Neurological disorders accounted for 11.1% of the consultations. The neurological disorders most frequently leading to consultations were headaches (42.7%), with primary headaches accounting for 16%; next came leprosy neuropathy (14.7%), with a worrisome total of 8 new cases; other peripheral neuropathies (13.3%), and epilepsy (12%). The relatively low share of the latter seems likely related to families' frequent use of traditional healers rather than Western medicine. Neurological diseases appears to represent a significant part of the health-care demand of people living in rural tropical areas of developing countries, and specific support in this specialization is essential.; La pathologie neurologique représente une part significative de la demande en santé des populations en milieu tropical rural des pays en développement, où un appui spécifique de la discipline neurologique semble indispensable

Published
2014

6. Genetic and Environmental Influences on the Visual Word Form and Fusiform Face Areas

Author

Stanislas Dehaene, Ghislaine Dehaene-Lambertz, Fabien Fauchereau, Thomas Bourgeron, Eric Artiges, Cyril Poupon, Denis Le Bihan, Philippe Pinel, Christophe Lalanne, Neuroimagerie cognitive - Psychologie cognitive expérimentale (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Saclay (COmUE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Chaire Psychologie cognitive expérimentale, Collège de France (CdF (institution)), Recherche Clinique ville-hôpital, Méthodologies et Société (REMES), Université Paris Diderot - Paris 7 (UPD7), Trouble du comportement alimentaire de l'adolescent, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris-Sud - Paris 11 (UP11), Gènes, Synapses et Cognition (CNRS - UMR3571 ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Fondation FondaMental [Créteil], Génétique humaine et fonctions cognitives - Human Genetics and Cognitive Functions (GHFC (UMR_3571 / U-Pasteur_1)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Service NEUROSPIN (NEUROSPIN), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Neuroimagerie en psychiatrie (U1000), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Sud - Paris 11 (UP11), This work was supported by Institut National de la Santé et de la Recherche Médicale (INSERM), Commissariat à l'Energie Atomique (CEA) and the James S. McDonnell Foundation., Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Collège de France - Chaire Psychologie cognitive expérimentale, Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroimagerie cognitive ( UNICOG-U992 ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Collège de France ( CDF ), Collège de France ( CdF ), Recherche Clinique ville-hôpital, Méthodologies et Société ( REMES ), Université Paris Diderot - Paris 7 ( UPD7 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris-Sud - Paris 11 ( UP11 ), Gènes, Synapses et Cognition, Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Génétique humaine et Fonctions cognitives - Human Genetics and Cognitive Functions, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Service NEUROSPIN ( NEUROSPIN ), Direction de Recherche Fondamentale (CEA) ( DRF (CEA) ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay, Neuroimagerie en psychiatrie ( U1000 ), Université Paris-Sud - Paris 11 ( UP11 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Neuroimagerie cognitive (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Collège de France (CDF), Collège de France (CdF), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut Pasteur [Paris], and Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)

Subjects
Male, MESH : Oxygen, MESH : Brain Mapping, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV]Life Sciences [q-bio], Statistics as Topic, MESH : Statistics as Topic, temporal, MESH : Photic Stimulation, Functional Laterality, MESH: Magnetic Resonance Imaging, [SCCO]Cognitive science, 0302 clinical medicine, Face perception, Stress (linguistics), Image Processing, Computer-Assisted, Twins, Dizygotic, Visual word form area, 10. No inequality, MESH: Brain Mapping, Language, Brain Mapping, medicine.diagnostic_test, 05 social sciences, MESH: Gene-Environment Interaction, MESH : Adult, Magnetic Resonance Imaging, MESH: Image Processing, Computer-Assisted, Temporal Lobe, MESH : Twins, Monozygotic, MESH: Photic Stimulation, Pattern Recognition, Visual, MESH: Young Adult, MESH: Language, Visual Perception, [ SCCO ] Cognitive science, MESH: Twins, Monozygotic, Psychology, MESH : Visual Perception, MESH : Image Processing, Computer-Assisted, MESH: Oxygen, VWFA, Cognitive psychology, Adult, MESH : Twins, Dizygotic, MESH : Male, Cognitive Neuroscience, MESH : Young Adult, MESH: Pattern Recognition, Visual, 050105 experimental psychology, Lateralization of brain function, Temporal lobe, Young Adult, 03 medical and health sciences, Cellular and Molecular Neuroscience, MESH : Language, reading, MESH : Magnetic Resonance Imaging, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, medicine, Humans, MESH: Temporal Lobe, 0501 psychology and cognitive sciences, MESH: Functional Laterality, MESH : Functional Laterality, MESH : Pattern Recognition, Visual, MESH : Temporal Lobe, MESH: Statistics as Topic, MESH: Humans, [ SDV ] Life Sciences [q-bio], MESH: Visual Perception, MESH: Twins, Dizygotic, MESH : Humans, MESH: Adult, Twins, Monozygotic, Fusiform face area, MESH: Male, MESH : Gene-Environment Interaction, Oxygen, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Gene-Environment Interaction, genetic, FFA, Functional magnetic resonance imaging, Photic Stimulation, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery, Spoken language
Abstract

International audience; Two areas of the occipitotemporal cortex show a remarkable hemispheric lateralization: written words activate the visual word form area (VWFA) in the left fusiform gyrus and faces activate a symmetrical site in the right hemisphere, the fusiform face area (FFA). While the lateralization of the VWFA fits with the leftward asymmetry of the speech processing network, origin of the rightward asymmetry for faces is still unclear. Using fMRI data from 64 subjects (including 16 monozygotic (MZ) and 13 dizygotic (DZ) twin pairs), we investigated how activations evoked by written words, faces, and spoken language are co-lateralized in the temporal lobe, and whether this organization reflects genetic factors or individual reading expertise. We found that the lateralization of the left superior temporal activation for spoken language correlates with the lateralization of occipitotemporal activations for both written words and faces. Behavioral reading scores also modulate the responses to words and faces. Estimation of genetic and environmental contributions shows that activations of the VWFA, the occipital face area, and the temporal speech areas are partially under genetic control whereas activation of the FFA is primarily influenced by individual experience. Our results stress the importance of both genetic factors and acquired expertise in the occipitotemporal organization.

Published
2014

7. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study

Author

Sandra Nolte, Laura L Laslett, Anthony D. Woolf, Emma Smith, Theo Vos, Damian G Hoy, Ilana N. Ackerman, Marita Cross, Richard H. Osborne, Marlene Fransen, Flavia M. Cicuttini, Lisa Bridgett, Rachelle Buchbinder, Graeme Jones, Lyn March, Sean R.M. Williams, Francis Guillemin, Christopher Hill, Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, School of Population Health, University of Queensland, Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, Institute of Public Health [Berlin, Germany], School of Health and Social Development [Deakin University], Deakin University [Burwood], The Royal Melbourne Hospital, Melbourne EpiCentre, Faculty of Health Sciences [University of Sydney], The University of Sydney, School of Medicine [Western Sydney University], Western Sydney University (UWS), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), The Queen Elizabeth Hospital, Adelaide, The Health Observatory [University of Adelaide], University of Adelaide, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, University of Tasmania (UTAS), Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia, Monash University [Clayton], Institute for Health Metrics and Evaluation [University of Washington], University of Washington [Seattle], Cabrini Institute, Monash University [Melbourne], Royal Cornwall Hospital, Royal North Shore Hospital ( RNSH ) -The University of Sydney [Sydney], Charite-Universitatsmedizin Berlin [Berlin], Hôpital universitaire de la Charité de Berlin, Melbourne Medical School-The Royal Melbourne Hospital, The University of Sydney [Sydney], Western Sydney University ( UWS ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université de Lorraine ( UL ) -Université Paris Descartes - Paris 5 ( UPD5 ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Western Sydney University, and University of Tasmania [Hobart, Australia] (UTAS)

Subjects
Male, MESH : Prevalence, Epidemiology, MESH : Age Distribution, MESH : Aged, MESH: Global Health, Osteoarthritis, MESH : Child, Preschool, Global Health, MESH: Regression Analysis, Severity of Illness Index, Osteoarthritis, Hip, MESH: Aged, 80 and over, MESH : Child, Cost of Illness, MESH : Regression Analysis, MESH: Child, MESH: Osteoarthritis, Knee, Prevalence, Immunology and Allergy, MESH : Cost of Illness, MESH : Female, MESH: Incidence, Young adult, Child, MESH : Sex Distribution, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Incidence, Incidence (epidemiology), MESH: Sex Distribution, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, MESH: Cost of Illness, Middle Aged, Osteoarthritis, Knee, MESH: Infant, MESH : Incidence, 3. Good health, MESH: Quality-Adjusted Life Years, MESH: Young Adult, Child, Preschool, Regression Analysis, MESH : Severity of Illness Index, Female, Quality-Adjusted Life Years, MESH : Osteoarthritis, Hip, Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, MESH : Male, Immunology, Population, MESH : Young Adult, General Biochemistry, Genetics and Molecular Biology, Knee Osteoarthritis, Young Adult, Age Distribution, Rheumatology, MESH : Adolescent, MESH: Severity of Illness Index, Severity of illness, medicine, Humans, MESH : Middle Aged, MESH : Osteoarthritis, Knee, Sex Distribution, MESH : Aged, 80 and over, education, MESH: Age Distribution, MESH: Prevalence, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Child, Preschool, Infant, MESH: Adult, MESH : Quality-Adjusted Life Years, medicine.disease, Obesity, MESH: Male, Quality-adjusted life year, Physical therapy, MESH : Global Health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Osteoarthritis, Hip, business, MESH: Female
Abstract

International audience; OBJECTIVE:To estimate the global burden of hip and knee osteoarthritis (OA) as part of the Global Burden of Disease 2010 study and to explore how the burden of hip and knee OA compares with other conditions.METHODS:Systematic reviews were conducted to source age-specific and sex-specific epidemiological data for hip and knee OA prevalence, incidence and mortality risk. The prevalence and incidence of symptomatic, radiographic and self-reported hip or knee OA were included. Three levels of severity were defined to derive disability weights (DWs) and severity distribution (proportion with mild, moderate and severe OA). The prevalence by country and region was multiplied by the severity distribution and the appropriate disability weight to calculate years of life lived with disability (YLDs). As there are no deaths directly attributed to OA, YLDs equate disability-adjusted life years (DALYs).RESULTS:Globally, of the 291 conditions, hip and knee OA was ranked as the 11th highest contributor to global disability and 38th highest in DALYs. The global age-standardised prevalence of knee OA was 3.8% (95% uncertainty interval (UI) 3.6% to 4.1%) and hip OA was 0.85% (95% UI 0.74% to 1.02%), with no discernible change from 1990 to 2010. Prevalence was higher in females than males. YLDs for hip and knee OA increased from 10.5 million in 1990 (0.42% of total DALYs) to 17.1 million in 2010 (0.69% of total DALYs).CONCLUSIONS:Hip and knee OA is one of the leading causes of global disability. Methodological issues within this study make it highly likely that the real burden of OA has been underestimated. With the aging and increasing obesity of the world's population, health professions need to prepare for a large increase in the demand for health services to treat hip and knee OA.

Published
2014

8. Patterns of physical activity and sedentary behaviour in the general population in France: cluster analysis with personal and socioeconomic correlates

Author

Joël Coste, Abdou Y. Omorou, Hélène Escalon, Anne Vuillemin, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Institut National de Prévention et d'Education pour la Santé (INPES), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), and Institut National de Prévention et d'Education pour la Santé ( INPES )

Subjects
Male, Pediatrics, MESH : Aged, Poison control, physical activity, Transportation, MESH: Logistic Models, Logistic regression, 0302 clinical medicine, MESH : Child, MESH : Exercise, Surveys and Questionnaires, MESH: Child, MESH : Socioeconomic Factors, Cluster Analysis, MESH : Female, 030212 general & internal medicine, clusters, MESH : Leisure Activities, Child, 2. Zero hunger, MESH: Aged, education.field_of_study, MESH: Middle Aged, 1. No poverty, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH : Adult, Middle Aged, 3. Good health, Homogeneous, MESH: Young Adult, Female, France, MESH : Surveys and Questionnaires, MESH: Sedentary Lifestyle, Adult, medicine.medical_specialty, MESH: Socioeconomic Factors, Adolescent, MESH : Male, Population, Physical activity, MESH : Young Adult, World health, socioeconomic status, 03 medical and health sciences, Young Adult, Leisure Activities, MESH : Adolescent, sedentary behaviour, medicine, MESH : Transportation, MESH : Cluster Analysis, Humans, MESH : Middle Aged, Occupations, MESH: Surveys and Questionnaires, education, MESH : France, Socioeconomic status, Exercise, MESH: Leisure Activities, Socioeconomic differences, Aged, MESH: Adolescent, MESH: Humans, MESH: Occupations, business.industry, MESH: Transportation, MESH : Humans, Public Health, Environmental and Occupational Health, MESH : Occupations, correlates, MESH: Adult, 030229 sport sciences, MESH: Cluster Analysis, MESH: Male, MESH: France, Logistic Models, Socioeconomic Factors, MESH: Exercise, MESH : Sedentary Lifestyle, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Sedentary Behavior, business, MESH: Female, Demography, MESH : Logistic Models
Abstract

International audience; BACKGROUND:Few studies have focused on relating physical activity (PA) and sedentary behaviour (SB) to identify homogeneous groups. This study aimed to identify patterns of PA and SB in France general population and their correlates.METHODS:A sample of 3294 (mean age 44 ± 17 years) from the general population in France was included. PA and SB were assessed by the World Health Organization Global Physical Activity Questionnaire. Cluster analysis was used to identify PA and SB patterns, with polytomous logistic regression to identify their correlates.RESULTS:Five clusters were identified: (i) 'low total PA, active-transportation and low SB' (41%), (ii) 'low total PA and moderate SB' (22%), (iii) 'low total PA, leisure-time PA and high SB' (15%), (iv) 'high total PA, moderate occupational PA and moderate SB' (17%) and (v) 'high total PA, vigorous occupational PA and low SB' (5%). Occupational PA substantially contributed to total PA which depended on socioeconomic status (SES): low total PA and high SB in higher SES and high total PA and low SB in lower SES.CONCLUSIONS:Based on PA and SB, French adults were clustered into groups with socioeconomic differences emphasizing that adapted interventions may be more beneficial for health.

Published
2016

9. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Author

Lakshmi Vijayakumar, H. Ross Anderson, David Singh, Doruk Ozgediz, Ted R. Miller, David Chou, Sumeet S. Chugh, Patricia J. Erwin, Samath D Dharmaratne, Steven E. Lipshultz, Roderick J. Hay, Pon Hsiu Yeh, Luigi Naldi, Valery L. Feigin, Patricia Espindola, Laurie M. Anderson, Beth E. Ebel, Ziad A. Memish, Victor Aboyans, Fiona M. Blyth, Derrick A Bennett, Richard H. Osborne, Mohammad H. Forouzanfar, Maria Segui-Gomez, Ella Sanman, Myles Connor, Esteban Porrini, Don C. Des Jarlais, John R. Condon, Gretchen L. Birbeck, Luc E. Coffeng, Tim Driscoll, David Bartels, Bishnu Pahari, G. Remuzzi, F.G.R. Fowkes, Kyle J Foreman, Joshua A. Salomon, Suzanne Barker-Collo, Mengru Wang, Leslie T. Cooper, Diego Gonzalez-Medina, Ali A. Mokdad, Andrea Panozo Rivero, George A. Mensah, Diana Haring, Julie O. Denenberg, Murugesan Raju, Ralph L. Sacco, Robin Marks, Ian Bolliger, Jeffrey A. Towbin, Rita Krishnamurthi, Dharani Ranganathan, David Phillips, Benjamin C Cowie, Paul S. F. Yip, Charles Mock, Bruno Hoen, Robert G. Weintraub, Frederick P. Rivara, Kaustubh Dabhadkar, Jonathan R. Carapetis, K. Ellicott Colson, Wenzhi Wang, Diego De Leo, Lisa M. Knowlton, Guy B. Marks, Michael S Lipnick, Rashmi Jasrasaria, Flavio Gaspari, Richard F. Gillum, John J. McGrath, Jacqueline Mabweijano, Rogelio Perez Padilla, Marlene Fransen, Allyne Delossantos, Theo Vos, Rafael Lozano, Damian G Hoy, Thomas Roberts, Anthony D. Woolf, Zhi Jie Zheng, Karen Sliwa, Andrew E. Moran, Boris Bikbov, Jessica Singleton, Spencer L. James, Mohsen Naghavi, Kim Mulholland, Saad B. Omer, Yara A. Halasa, Sherine E. Gabriel, Leslie Mallinger, Peter Burney, Imad M. Tleyjeh, Majid Ezzati, Jennifer A. Taylor, Thomas Truelsen, Akira Matsumori, Emelia J. Benjamin, Mary M. McDermott, Kiumarss Nasseri, James Harrison, Honglei Chen, Emmanuela Gakidou, M. Nathan Nair, Jerry Abraham, Karen Courville De Vaccaro, Kenji Shibuya, Rakesh Aggarwal, Stephanie Y. Ahn, Steven D. Colan, Christopher J L Murray, Aref A. Bin Abdulhak, Michael Burch, Tony R. Merriman, Nabila Dahodwala, Sudha Jayaraman, Catherine Michaud, Louisa Degenhardt, C. Arden Pope, Monica Cortinovis, Richard Matzopoulos, Norberto Perico, Matthew A. Corriere, Kelsey Pierce, Charles Atkinson, Tim Adair, Abraham D. Flaxman, Michael F. Macintyre, Gregory R. Wagner, Paul Norman, Herbert C. Duber, Kathryn H. Jacobsen, Peter J. Hotez, Andre Keren, Felipe Rodriguez De Leòn, Samantha M. Colquhoun, Michael H. Criqui, Kavi Bhalla, Soufiane Boufous, Narayanaswamy Venketasubramanian, Alan D. Lopez, Larry M. Baddour, Ana Olga Mocumbi, David B. Rein, Jürgen Rehm, Stephen S Lim, Farshad Pourmalek, Nicole E. Johns, Ganesan Karthikeyan, Martin A. Weinstock, Lyn March, Donald S. Shepard, K.M. Venkat Narayan, Michael Freeman, Chiara Bucello, Nicholas J Kassebaum, Adofo Koranteng, Eduardo A. Undurraga, Kerrianne Watt, Mohammad A. AlMazroa, Marita Cross, Fernando Perez-Ruiz, Rasmus Havmoeller, Uchechukwu Sampson, Emma Smith, Bongani M. Mayosi, Summer Lockett Ohno, Michelle L. Bell, John H. McAnulty, E. Ray Dorsey, Lesley Rushton, Matthew J. Miller, Azadeh Zabetian, James D. Wilkinson, David C. Schwebel, Olive Kobusingye, Katrina F Ortblad, Martin O'Donnell, Jon Paul Khoo, William G. Couser, Miriam Alvarado, Richard C. Franklin, Lisa C. Rosenfeld, Andrew C Steer, Bernadette Thomas, Jeyaraj D Pandian, Sarah Wulf, Kathryn G. Andrews, Neuroépidémiologie Tropicale ( NET ), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Respiratory Epidemiology and Public Health, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Cisco Systems, CISCO Systems, Inc, Department of dermatology, Milano University-Azienda Ospedaleria Ospedali Riuniti di Bergamo, centre for photomolecular science, Imperial College London, Department of neurology, Miller School of Medicine-University of Miami [Coral Gables], Département Cité des métiers - Cité de la santé - Universcience ( CDM/CDS ), Cité des Sciences et de l'Industrie, Public Health, Cell biology, Cardiothoracic Surgery, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, University of Miami [Coral Gables]-University of Miami Leonard M. Miller School of Medicine (UMMSM), and Département Cité des métiers - Cité de la santé - Universcience (CDM/CDS)

Subjects
Male, Pediatrics, MESH : Mortality, MESH : Aged, Poison control, Disease, MESH : Child, Preschool, 030204 cardiovascular system & hematology, Global Health, MESH: Cause of Death, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Child, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Cause of Death, MESH: Child, MESH : Female, 030212 general & internal medicine, Child, Cause of death, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, Mortality rate, MESH: Infant, Newborn, Age Factors, 1. No poverty, MESH : Infant, General Medicine, Middle Aged, MESH : Adult, MESH: Infant, 3. Good health, MESH : World Health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Young Adult, Child, Preschool, Female, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Sex Factors, Population, MESH : Young Adult, MESH : Infant, Newborn, Young Adult, 03 medical and health sciences, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, MESH : Adolescent, Injury prevention, medicine, Humans, MESH : Middle Aged, Mortality, MESH : Aged, 80 and over, education, Aged, MESH : Cause of Death, MESH: Adolescent, MESH: Age Factors, MESH: Humans, MESH: Mortality, business.industry, MESH: Child, Preschool, MESH : Humans, Infant, Newborn, Infant, MESH: Adult, Verbal autopsy, MESH: Male, Years of potential life lost, MESH : Age Factors, business, MESH: Female, MESH: World Health, Demography
Abstract

International audience; BACKGROUND: Reliable and timely information on the leading causes of death in populations, and how these are changing, is a crucial input into health policy debates. In the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010), we aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex. METHODS: We attempted to identify all available data on causes of death for 187 countries from 1980 to 2010 from vital registration, verbal autopsy, mortality surveillance, censuses, surveys, hospitals, police records, and mortuaries. We assessed data quality for completeness, diagnostic accuracy, missing data, stochastic variations, and probable causes of death. We applied six different modelling strategies to estimate cause-specific mortality trends depending on the strength of the data. For 133 causes and three special aggregates we used the Cause of Death Ensemble model (CODEm) approach, which uses four families of statistical models testing a large set of different models using different permutations of covariates. Model ensembles were developed from these component models. We assessed model performance with rigorous out-of-sample testing of prediction error and the validity of 95% UIs. For 13 causes with low observed numbers of deaths, we developed negative binomial models with plausible covariates. For 27 causes for which death is rare, we modelled the higher level cause in the cause hierarchy of the GBD 2010 and then allocated deaths across component causes proportionately, estimated from all available data in the database. For selected causes (African trypanosomiasis, congenital syphilis, whooping cough, measles, typhoid and parathyroid, leishmaniasis, acute hepatitis E, and HIV/AIDS), we used natural history models based on information on incidence, prevalence, and case-fatality. We separately estimated cause fractions by aetiology for diarrhoea, lower respiratory infections, and meningitis, as well as disaggregations by subcause for chronic kidney disease, maternal disorders, cirrhosis, and liver cancer. For deaths due to collective violence and natural disasters, we used mortality shock regressions. For every cause, we estimated 95% UIs that captured both parameter estimation uncertainty and uncertainty due to model specification where CODEm was used. We constrained cause-specific fractions within every age-sex group to sum to total mortality based on draws from the uncertainty distributions. FINDINGS: In 2010, there were 52*8 million deaths globally. At the most aggregate level, communicable, maternal, neonatal, and nutritional causes were 24*9% of deaths worldwide in 2010, down from 15*9 million (34*1%) of 46*5 million in 1990. This decrease was largely due to decreases in mortality from diarrhoeal disease (from 2*5 to 1*4 million), lower respiratory infections (from 3*4 to 2*8 million), neonatal disorders (from 3*1 to 2*2 million), measles (from 0*63 to 0*13 million), and tetanus (from 0*27 to 0*06 million). Deaths from HIV/AIDS increased from 0*30 million in 1990 to 1*5 million in 2010, reaching a peak of 1*7 million in 2006. Malaria mortality also rose by an estimated 19*9% since 1990 to 1*17 million deaths in 2010. Tuberculosis killed 1*2 million people in 2010. Deaths from non-communicable diseases rose by just under 8 million between 1990 and 2010, accounting for two of every three deaths (34*5 million) worldwide by 2010. 8 million people died from cancer in 2010, 38% more than two decades ago; of these, 1*5 million (19%) were from trachea, bronchus, and lung cancer. Ischaemic heart disease and stroke collectively killed 12*9 million people in 2010, or one in four deaths worldwide, compared with one in five in 1990; 1*3 million deaths were due to diabetes, twice as many as in 1990. The fraction of global deaths due to injuries (5*1 million deaths) was marginally higher in 2010 (9*6%) compared with two decades earlier (8*8%). This was driven by a 46% rise in deaths worldwide due to road traffic accidents (1*3 million in 2010) and a rise in deaths from falls. Ischaemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), lower respiratory infections, lung cancer, and HIV/AIDS were the leading causes of death in 2010. Ischaemic heart disease, lower respiratory infections, stroke, diarrhoeal disease, malaria, and HIV/AIDS were the leading causes of years of life lost due to premature mortality (YLLs) in 2010, similar to what was estimated for 1990, except for HIV/AIDS and preterm birth complications. YLLs from lower respiratory infections and diarrhoea decreased by 45-54% since 1990; ischaemic heart disease and stroke YLLs increased by 17-28%. Regional variations in leading causes of death were substantial. Communicable, maternal, neonatal, and nutritional causes still accounted for 76% of premature mortality in sub-Saharan Africa in 2010. Age standardised death rates from some key disorders rose (HIV/AIDS, Alzheimer's disease, diabetes mellitus, and chronic kidney disease in particular), but for most diseases, death rates fell in the past two decades; including major vascular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders. For other conditions, notably malaria, prostate cancer, and injuries, little change was noted. INTERPRETATION: Population growth, increased average age of the world's population, and largely decreasing age-specific, sex-specific, and cause-specific death rates combine to drive a broad shift from communicable, maternal, neonatal, and nutritional causes towards non-communicable diseases. Nevertheless, communicable, maternal, neonatal, and nutritional causes remain the dominant causes of YLLs in sub-Saharan Africa. Overlaid on this general pattern of the epidemiological transition, marked regional variation exists in many causes, such as interpersonal violence, suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others. Regional heterogeneity highlights the importance of sound epidemiological assessments of the causes of death on a regular basis. FUNDING: Bill & Melinda Gates Foundation.

Published
2012

10. Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study

Author

Valérie Jooste, Zoé Uhry, Anne-Marie Bouvier, Jean Faivre, Sophie Grabar, N. Duport, Sylvain Manfredi, Aurélien Belot, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), FRANCIM, Réseau des registres français du cancer, Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de Biostatistiques [Lyon], Hospices Civils de Lyon (HCL), Service des Maladies de l'Appareil Digestif [CHU Rennes], CHU Pontchaillou [Rennes], Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National du Cancer (INCA), Santé publique France, Pontchaillou. Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire [Rennes], Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Centre Hospitalier Universitaire de Rennes, and Institut National de la Santé et de la Recherche Médicale ( INSERM )

Subjects
Male, Epidemiology, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Anus Neoplasms, MESH: Research Papers: Gastrointestinal Cancer, 0302 clinical medicine, MESH : Child, MESH: Child, Medicine, MESH: Incidence, MESH : Carcinoma, Squamous Cell, Child, education.field_of_study, MESH: Middle Aged, Obstetrics, MESH : Infant, MESH: Carcinoma, Squamous Cell, MESH: Follow-Up Studies, Anal canal, Anus Neoplasms, Prognosis, Research Papers, MESH: Infant, MESH : Incidence, 3. Good health, Survival Rate, Oncology, MESH: Young Adult, Child, Preschool, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, 030211 gastroenterology & hepatology, medicine.medical_specialty, MESH : Research Papers: Gastrointestinal Cancer, Mitomycin, MESH : Young Adult, United-States, MESH: Prognosis, 03 medical and health sciences, MESH : Adolescent, Humans, Anal cancer, MESH : Middle Aged, MESH : Anus Neoplasms, education, Aged, Gynecology, MESH: Adolescent, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Public Health, Environmental and Occupational Health, Infant, MESH : Follow-Up Studies, MESH: Adult, Epidermoid Carcinoma, medicine.disease, Cervical-cancer, incidence, Randomized-trial, MESH: Female, Cancer Research, MESH: Registries, MESH : Child, Preschool, Risk Factors, MESH: Risk Factors, MESH : Female, Registries, Cervical cancer, MESH: Aged, MESH : Prognosis, Incidence (epidemiology), Smoking, MESH: Infant, Newborn, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, medicine.anatomical_structure, Female, France, Adult, Human-Papillomavirus, Risk, Adolescent, MESH: Survival Rate, anal cancer, MESH : Male, Population, Human Papilloma Virus Vaccine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cancer Incidence, MESH : Infant, Newborn, survival, Young Adult, cancer registry, MESH : France, Survival rate, Radiotherapy, business.industry, Infant, Newborn, Cancer, MESH: Male, MESH: France, business, MESH : Registries, Follow-Up Studies
Abstract

IF 2.415; International audience; Data on anal cancer epidemiology are rare. The aim of this study was to report on trends of incidence and survival for anal cancer in France before the implementation of the human papilloma virus vaccine. This analysis was carried out on 1150 squamous-cell carcinomas of the anal canal diagnosed from 1989 to 2004 in a population of 5.7 million people covered by eight population-based cancer registries. Time trends in incidence were modeled using an age-period-cohort model. Net survival rates were obtained using the recently validated unbiased Pohar-Perme estimator. The incidence of squamous-cell carcinoma of the anal canal increased from 0.2 to 0.5/100 000 person-years among men and from 0.7 to 1.3/100 000 person-years among women from 1982 to 2012. Among women, the increase peaked after 2005, with an annual percentage change of +3.4% between 2005 and 2012, as compared with +2.6% among men. The net survival was 56% (95% confidence interval, 49-64) at 5 years and 48% (33-70) at 10 years among men. It was higher among women, at 65% (61-69) and 56% (50-63) at 5 and 10 years, respectively. The prognosis improved between 1989-1997 and 1998-2004. This improvement was slightly greater for men than for women, thus progressively reducing the gap between sexes. The incidence of squamous-cell anal canal cancer increased slightly among both sexes, but the increase was more marked among women than among men. The potential benefit of prophylactic female human papilloma virus vaccination against cervical cancer in France should be further evaluated.

Published
2016

11. Clinical epidemiology and resistance mechanisms of carbapenem-resistant Acinetobacter baumannii, French Guiana, 2008-2014

Author

Magalie Demar, Pierre Couppié, Hatem Kallel, Mathieu Nacher, Christine Simonnet, Didier Hommel, Félix Djossou, Aba Mahamat, Xavier Bertrand, B. Moreau, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Institut de l’Élevage, Centre Hospitalier Andrée-Rosemond, Epidemiologie des Parasitoses Tropicales ( EPaT Team ), Université des Antilles et de la Guyane ( UAG ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Département de Biologie, Unité de Biochimie des Lipides et des Protéines, Faculté des Sciences de Tunis, Ecosystemes Amazoniens et Pathologie Tropicale ( EPat ), Université de Guyane ( UG ) -Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles ( UA ), Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyanne Française], Centre d'investigation clinique Antilles-Guyane ( CIC - Antilles Guyane ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine ( COREVIH Guyane ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Faculté des Sciences Mathématiques, Physiques et Naturelles de Tunis (FST), Université de Tunis El Manar (UTM)-Université de Tunis El Manar (UTM), Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA), Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], and Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH Guyane)

Subjects
0301 basic medicine, Male, Acinetobacter baumannii, Imipenem, MESH : Retrospective Studies, Epidemiology, MESH : Multilocus Sequence Typing, MESH: beta-Lactamases, MESH : Carbapenems, Disease Outbreaks, MESH: Carbapenems, Disk Diffusion Antimicrobial Tests, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, polycyclic compounds, MESH : Bacterial Proteins, Pharmacology (medical), MESH : Female, MESH: Disease Outbreaks, MESH: Bacterial Proteins, Cross Infection, Molecular Epidemiology, MESH: Middle Aged, biology, MESH : beta-Lactamases, General Medicine, Middle Aged, MESH : Adult, MESH: Hospitals, Hospitals, 3. Good health, Electrophoresis, Gel, Pulsed-Field, French Guiana, MESH : Hospitals, Infectious Diseases, MESH: Multilocus Sequence Typing, MESH: Electrophoresis, Gel, Pulsed-Field, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Amikacin, MESH: Young Adult, MESH: Disk Diffusion Antimicrobial Tests, Female, MESH: Acinetobacter Infections, MESH : Cross Infection, medicine.drug, Acinetobacter Infections, Microbiology (medical), Adult, MESH : French Guiana, MESH : Male, 030106 microbiology, MESH : Molecular Epidemiology, MESH : Young Adult, Tazobactam, beta-Lactam Resistance, beta-Lactamases, Microbiology, Carbapenem-resistant, 03 medical and health sciences, Young Adult, Bacterial Proteins, MESH : beta-Lactam Resistance, MESH: French Guiana, medicine, Humans, MESH: Molecular Epidemiology, MESH : Acinetobacter Infections, Intensive care unit, MESH : Middle Aged, MESH : Disease Outbreaks, MESH : Disk Diffusion Antimicrobial Tests, MESH : Acinetobacter baumannii, Retrospective Studies, MESH : Electrophoresis, Gel, Pulsed-Field, MESH: Humans, Molecular epidemiology, business.industry, MESH: Acinetobacter baumannii, MESH : Humans, Outbreak, MESH: Cross Infection, MESH: Retrospective Studies, MESH: Adult, biochemical phenomena, metabolism, and nutrition, biology.organism_classification, bacterial infections and mycoses, MESH: Male, MESH: beta-Lactam Resistance, Carbapenems, Colistin, Nosocomial, business, MESH: Female, Piperacillin, Multilocus Sequence Typing
Abstract

International audience; This study investigated the clinical epidemiology and resistance mechanisms of Acinetobacter baumannii and characterised the clonal diversity of carbapenem-resistant A. baumannii (CRAB) during an ICU-associated outbreak at Cayenne Hospital, French Guiana. All non-duplicate A. baumannii isolates from 2008 to 2014 were tested for antibiotic susceptibility by disk diffusion. Multilocus sequence typing, pulsed-field gel electrophoresis (PFGE) and characterisation of carbapenemase-encoding genes were performed on CRAB. Of the 441 A. baumannii isolates, most were from males (54.0%) and were detected mainly from the ICU (30.8%) and medicine wards (21.8%). In the ICU, strains were mainly isolated from the respiratory tract (44.1%) and bloodstream (14.0%), whereas in medicine wards they mainly were from wound/drainage (36.5%) and bloodstream (25.0%). A. baumannii showed the greatest susceptibility to piperacillin/tazobactam (92.7%), imipenem (92.5%), colistin (95.6%) and amikacin (97.2%), being lower in the ICU and medicine wards compared with other wards. An outbreak of OXA-23-producing CRAB occurred in the 13-bed ICU in 2010. CRAB strains were more co-resistant to other antimicrobials compared with non-CRAB. Molecular genetics analysis revealed five sequence types [ST78, ST107 and ST642 and two new STs (ST830 and ST831)]. Analysis of PFGE profiles indicated cross-transmissions of CRAB within the ICU, between the ICU and one medicine ward during transfer of patients, and within that medicine ward. This study provides the first clinical and molecular data of A. baumannii from French Guiana and the Amazon basin. The ICU was the highest risk unit of this nosocomial outbreak of OXA-23-producing CRAB, which could subsequently disseminate within the hospital.

Published
2016

12. Bronchoalveolar Lavage in Hypersensitivity Pneumonitis: A Series of 139 Patients

Author

Caillaud, Denis M, Vergnon, Jean M, Madroszyk, Anne, Melloni, Boris M, Murris, Marlene, Dalphin, Jean-Charles, Renseigné, Non, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Chrono-environnement ( LCE ), and Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC )

Subjects
Male, Pathology, Lymphocyte, MESH : Aged, Bronchoalveolar Lavage, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH : Farmer's Lung, MESH: Aged, 80 and over, Immunology and Allergy, Eosinophilia, MESH : Female, Aged, 80 and over, MESH: Aged, MESH : Bronchoalveolar Lavage Fluid, MESH: Middle Aged, MESH: Bronchoalveolar Lavage, medicine.diagnostic_test, General Medicine, Middle Aged, MESH : Adult, respiratory system, medicine.anatomical_structure, MESH: Young Adult, Female, medicine.symptom, Bronchoalveolar Lavage Fluid, MESH : Bronchoalveolar Lavage, Hypersensitivity pneumonitis, Alveolitis, Extrinsic Allergic, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Alveolitis, Extrinsic Allergic, Immunology, CD4-CD8 Ratio, MESH : Young Adult, MESH: Alveolitis, Extrinsic Allergic, Young Adult, Antigen, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, MESH: Adolescent, MESH: Farmer's Lung, Pharmacology, MESH: Humans, Lung, MESH: Bronchoalveolar Lavage Fluid, business.industry, MESH : Humans, MESH: Adult, medicine.disease, MESH: Male, Neutrophilia, respiratory tract diseases, Bronchoalveolar lavage, MESH : CD4-CD8 Ratio, Farmer's Lung, MESH: CD4-CD8 Ratio, business, MESH: Female, [ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, CD8
Abstract

International audience; Hypersensitivity pneumonitis (HP) is characterized by a lymphocytic alveolitis, classically delineated by an increase of CD8+ lymphocytes, with an inversion of the CD4+/CD8+ ratio. The aim of this study is both to describe the yield and cell bronchoalveolar lavage (BAL) profile and to revisit the assumption of low BAL CD4/CD8 ratio in the diagnosis of HP. A multicentric study was conducted on 139 patients who fulfilled the standardized diagnostic criteria of HP, mainly affected by farmer's lung. Mean total cell count in BAL fluid was 594 ± 401.10(3) cells /ml. Prominent absolute lymphocytic alveolitis, moderate neutrophilia, and mild eosinophilia and mastocytosis were found. Mean CD4/CD8 ratio was 3.8 ± 6.1 (median 2.1). Thirty four percent of the patients showed lymphocytic CD8 alveolitis (ratio < 1). The CD4/CD8 ratio was not different between forms, etiologies of HP, and time elapsed since last antigen exposure, but was higher in women (p=0.02). BAL in HP shows high total cell and lymphocyte counts, moderate neutrophilia, and mild eosinophilia and mastocytosis. An absence of low CD4/CD8 ratio should not at all exclude diagnosis.

Published
2012

13. Oncogenic Alterations in Papillary Thyroid Cancers of Young Patients

Author

G. Sassolas, Z. Hafdi Nejjari, A. Ferraro, M. S. Gandhi, C. Kwon Jung, E. Borbone, M. Decaussin Petrucci, B. Rousset, F. Borson Chazot, N. Berger, FUSCO, ALFREDO, registre rhone-alpin du cancer de la thyroide, Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-registre rhone-alpins du cancer de la thyroide, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), departement de pathologie, Hospices Civils de Lyon ( HCL ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -registre rhone-alpins du cancer de la thyroide, Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), G., Sassola, Z., Hafdi Nejjari, A., Ferraro, M. S., Gandhi, C., Kwon Jung, E., Borbone, M., Decaussin Petrucci, B., Rousset, F., Borson Chazot, N., Berger, and Fusco, Alfredo

Subjects
Male, Oncology, Pathology, Oncogene Proteins, Fusion, endocrine system diseases, MESH: Carcinoma, Papillary, Endocrinology, Diabetes and Metabolism, Disease, MESH : Oncogene Proteins, Fusion, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Endocrinology, MESH : Child, MESH: Child, MESH : Female, Young adult, Child, Lymph node, education.field_of_study, MESH : Prognosis, MESH : Genes, ras, Thyroid, Age Factors, Protein-Tyrosine Kinases, MESH : Adult, Prognosis, 3. Good health, medicine.anatomical_structure, Thyroid Cancer, Papillary, MESH: Thyroid Neoplasms, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, Mitogen-Activated Protein Kinases, MESH : Mutation, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, MESH: Mutation, Adolescent, MESH : Male, Population, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030209 endocrinology & metabolism, MESH: Protein-Tyrosine Kinases, MESH: Prognosis, MESH : Carcinoma, Papillary, Thyroid carcinoma, Young Adult, 03 medical and health sciences, Median follow-up, MESH : Adolescent, Internal medicine, MESH : Protein-Tyrosine Kinases, medicine, Humans, Thyroid Neoplasms, education, MESH : Proto-Oncogene Proteins B-raf, MESH: Adolescent, MESH: Age Factors, MESH: Proto-Oncogene Proteins B-raf, MESH: Humans, business.industry, Carcinoma, MESH : Humans, MESH : Mitogen-Activated Protein Kinases, MESH: Adult, MESH: Mitogen-Activated Protein Kinases, Carcinoma, Papillary, MESH : Thyroid Neoplasms, MESH: Male, MESH: Genes, ras, Genes, ras, Mutation, MESH : Age Factors, business, MESH: Female, V600E, MESH: Oncogene Proteins, Fusion
Abstract

International audience; BACKGROUND: Papillary thyroid carcinoma (PTC) in young people usually has an aggressive initial presentation, though a good general prognosis despite recurrences in 10%-20% of patients. A number of genetic alterations that activate the mitogen-activated protein kinase (MAPK) pathway have been found in PTC. Some of these alterations have been identified as prognostic factors of PTC in adults. The objective of the current study was to comprehensively characterize all known oncogenic alterations of the MAPK pathway in young people. METHODS: One hundred three PTCs removed from 9 children, 19 adolescents, and 75 young adults were submitted to molecular analyses. RESULTS: Altogether, 57 alterations were found in 56 PTCs (55%) corresponding to V600E BRAF in 20.3%, RAS mutations in 12.6%, RET/PTC 1 in 11.6%, RET/PTC 3 in 8.7%, and rearrangement of NTRK in 1.9%. The prevalence of all alterations increased with age (22.2% in children; 52.6% in adolescents, 51.4% in adults 20-25 years, and 55.1% in adults 25-35 years). Prevalence increased from 39.2% earlier to 61.3% after 20 years mainly due to BRAF mutations. Classic-type PTC was associated with a larger prevalence of alterations, predominantly BRAF and RET/PTC, whereas the follicular variant was chiefly associated with RAS. RET/PTC (1 and 3) was significantly associated with extrathyroid extension (ET) and lymph node metastasis (es) (LNM). This association was found in the adult group. There were no associations of BRAF or RAS mutations with ET or LNM. A 3-year median follow up was available for 90 patients. RET/PTC 1 and 3 was associated with short-term disease dissemination (cervical lymph node recurrences and distant metastases) in young adults (p=0.001). Persistent illness was more prevalent in patients with (15%) than in patients without (7%) genetic alterations. CONCLUSION: PTCs in young patients display a low prevalence of the already identified oncogenic alterations. The increasing prevalence with age is mainly due to V600E BRAF mutation. There is no relation between tumor aggressiveness and BRAF mutation. There is a relation between the presence of RET/PTC (1 and 3) and the histological and clinical short-term aggressiveness of PTC in the population of young adults. Such a relation is not found in children and adolescents.

Published
2012

14. Differential item functioning (DIF) of SF-12 and Q-LES-Q-SF items among french substance users

Author

Stéphanie Bourion-Bédès, Cédric Baumann, Alex Bédès, Vincent Laprevote, Jean Louis Bonnet, Raymund Schwan, Service médico-psychologique régional - Metz, Centre d'Addictovigilance de Nancy [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Centre de soin, d'accompagnement et de prévention en addictologie - Cantal ( C.S.A.P.A. 15 Aurillac ), ESPRI-Biobase [CHRU Nancy] ( Unité fonctionnelle de la plateforme d’aide à la recherche clinique ), Centre d'Addictovigilance de Nancy [CHRU Nancy] (CEIP-A Nancy), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre de soin, d'accompagnement et de prévention en addictologie - Cantal (C.S.A.P.A. 15 Aurillac), and ESPRI-Biobase [CHRU Nancy] (Unité fonctionnelle de la plateforme d’aide à la recherche clinique)

Subjects
Male, Psychometrics, Cross-sectional study, Opiate dependence, MESH : Mental Health, Developmental psychology, MESH : Cross-Sectional Studies, Quality of life, Surveys and Questionnaires, MESH : Female, MESH: Middle Aged, Substance dependence, MESH: Mental Health, MESH : Psychometrics, Alcohol dependence, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, Middle Aged, MESH : Adult, humanities, 3. Good health, MESH: Reproducibility of Results, Mental Health, MESH: Young Adult, MESH: Substance-Related Disorders, Female, France, Psychology, MESH : Surveys and Questionnaires, Adult, MESH : Substance-Related Disorders, Substance-Related Disorders, MESH : Male, MESH: Factor Analysis, Statistical, MESH : Young Adult, MESH : Factor Analysis, Statistical, Differential Item Functioning, behavioral disciplines and activities, Young Adult, MESH: Cross-Sectional Studies, MESH: Psychometrics, medicine, Humans, MESH : Middle Aged, MESH: Surveys and Questionnaires, MESH : France, Rasch model, MESH: Humans, Self-reported health status, Research, MESH : Reproducibility of Results, MESH : Humans, Public Health, Environmental and Occupational Health, Reproducibility of Results, MESH: Quality of Life, MESH: Adult, MESH : Quality of Life, medicine.disease, Mental health, Differential item functioning, Q-LES-Q-SF, MESH: Male, MESH: France, Cross-Sectional Studies, Quality of Life, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Factor Analysis, Statistical, MESH: Female
Abstract

International audience; BackgroundDifferential Item Functioning (DIF) is investigated to ensure that each item displays a consistent pattern of responses irrespective of the characteristics of the respondents. Assessing DIF helps to understand the nature of instruments, to assess the quality of a measure and to interpret results. This study aimed to examine whether the items of the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) and Short-Form 12 (SF-12) exhibit DIF.MethodA total of 124 outpatients diagnosed with substance dependence participated in a cross-sectional, multicenter study. In addition to the Q-LES-Q-SF and SF-12 results, demographic data such as age, sex, type of substance dependence and education level were collected. Rasch analysis was conducted (using RUMM2020 software) to assess DIF of the Q-LES-Q-SF and SF-12 items.ResultsFor SF-12, significant age-related uniform DIF was found in two of the 12 items, and sex-related DIF was found in one of the 12 items. All of the observed DIF effects in SF-12 were found among the mental health items. Three items showed DIF on the Q-LES-Q-SF; however, the impact of DIF item on the delta score calculation for the comparisons of self-reported health status between the groups was minimal in the SF-12 and small in the Q-LES-Q-SF.ConclusionThese results indicated that no major measurement bias affects the validity of the self-reported health status assessed using the Q-LES-Q-SF or SF-12. Thus, these questionnaires are largely robust measures of self-reported health status among substance users.

Published
2015

15. Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: a follow-up study from 2008 to 2011 in southeastern France

Author

Céline Pulcini, Pierre Verger, Ludovic Casanova, Sébastien Cortaredona, Patrick Peretti-Watel, Odile Launay, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), ORS PACA, REseau national d'Investigation clinique en VACcinologie ( REIVAC ), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 ( UPD5 ) -Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP]

Subjects
Male, Pediatrics, MESH : Aged, Type 2 diabetes, Care management, Logistic regression, MESH: Influenza Vaccines, MESH: Aged, 80 and over, MESH : Diabetes Mellitus, Type 2, Epidemiology, MESH : Socioeconomic Factors, MESH: Physicians, MESH : Female, MESH : Influenza, Human, Reimbursement, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Influenza, Human, Age Factors, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH: Follow-Up Studies, Middle Aged, MESH : Adult, 3. Good health, Vaccination, Infectious Diseases, Influenza Vaccines, MESH: Young Adult, Cohort, Female, epidemiology, multilevel analysis, France, patient, MESH: Diabetes Mellitus, Type 2, Adult, Microbiology (medical), medicine.medical_specialty, MESH: Socioeconomic Factors, diabetes mellitus type 2, Adolescent, Influenza vaccine, MESH : Male, MESH : Physicians, MESH : Young Adult, determinant, Young Adult, Physicians, Diabetes mellitus, MESH : Adolescent, Influenza, Human, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH : France, Aged, MESH: Adolescent, MESH: Age Factors, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, MESH: Vaccination, medicine.disease, vaccination, MESH: Male, MESH : Influenza Vaccines, MESH: France, Diabetes Mellitus, Type 2, Socioeconomic Factors, MESH : Vaccination, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Age Factors, influenza vaccine, business, MESH: Female, Follow-Up Studies
Abstract

International audience; We studied a cohort of 110 823 patients treated with oral hypoglycaemic agents for type 2 diabetes in southeastern France from 1 January 2008 to 31 December 2011, to identify influenza vaccination coverage trends and the patient and physician correlates of influenza vaccine (IFV) uptake. We used French national health insurance fund (NHIF) databases to identify these patients and collect data on their IFV reimbursement claims (IFVC) and patient and physician characteristics. We used multilevel multivariate polytomous logistic regressions to test the correlates of IFVC. Between 2008 and 2011 the annual IFVC rate varied from 33.7% to 32.3% in the 18-64 age group and from 69.5% to 61.1% in the 65 + age group, among whom we saw a clear trend towards reduced vaccination after 2008. In the younger group, the probability of regular vaccination each year from 2008 to 2011 increased with diabetes severity and duration, comorbidities, and the number of general practitioner and nurse visits; it was higher among patients seeing endocrinologists and lower among low-income patients than in other patients. In the older group, there was no association with either diabetes severity or physician specialty. These results suggest different patterns of correlates of influenza vaccination according to age. Endocrinologists might help to improve IFV uptake in the younger group of patients with type 2 diabetes. Communication strategies regarding influenza vaccination should be adapted to age, and collaboration between healthcare professionals should be reinforced to achieve vaccination objectives for these patients.

Published
2015

16. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)

Author

Stéphane Bretagne, B. Lebeau, F. de Monbrison, Olivier Lortholary, Karine Sitbon, Françoise Dromer, Jean-Pierre Gangneux, Bruno Coignard, Y. Le Strat, Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de Parasitologie-Mycologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Laboratoire de parasitologie-mycologie, CHU Grenoble, Laboratoire de Parasitologie-Mycologie, Centre Hospitalo-Universitaire de Lyon, Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Biologie moléculaire et immunologie parasitaires et fongiques (BIPAR), École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Dozulé, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Veille Sanitaire, Laboratoire de santé animale, sites de Maisons-Alfort et de Dozulé, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire d'Alfort (ENVA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Université de Rennes (UR), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Normandie, CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire ( CNRMA ), Signalisation et Réponses aux Agents Infectieux et Chimiques ( SeRAIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Biologie moléculaire et immunologie parasitaires et fongiques ( BIPAR ), Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -AFSSA-Ecole Nationale Vétérinaire d'Alfort-Institut National de la Recherche Agronomique ( INRA ), CHU Necker - Enfants Malades [AP-HP], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-IFR140, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
Male, Epidemiology, MESH : Prospective Studies, MESH : Aged, Aspergillosis, Mannans, 0302 clinical medicine, MESH: Immunocompromised Host, Prospective Studies, MESH: Incidence, Aged, 80 and over, Invasive Pulmonary Aspergillosis, 0303 health sciences, MESH: Middle Aged, Incidence, General Medicine, MESH : Incidence, 3. Good health, Aspergillus, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Young Adult, Drug Therapy, Combination, Microbiology (medical), MESH: Invasive Pulmonary Aspergillosis, medicine.medical_specialty, MESH : Young Adult, 03 medical and health sciences, Galactomannan, Pharmacotherapy, MESH: Mannans, MESH : Adolescent, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, MESH: Adolescent, MESH: Humans, MESH : Seasons, 030306 microbiology, MESH : Humans, MESH: Adult, MESH: Antifungal Agents, medicine.disease, chemistry, galactomannan, Immunology, MESH: Female, Antifungal Agents, chemistry.chemical_compound, MESH: Aged, 80 and over, Risk Factors, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Risk Factors, MESH : Female, 030212 general & internal medicine, Prospective cohort study, MESH: Aged, Incidence (epidemiology), MESH : Aspergillus, MESH : Immunocompromised Host, Middle Aged, MESH : Adult, MESH: Hospitals, MESH : Risk Factors, Hospitals, MESH : Hospitals, Infectious Diseases, MESH: Aspergillus, outcome, Female, France, Seasons, medicine.drug, Adult, Adolescent, MESH : Male, MESH : Antifungal Agents, Immunocompromised Host, Young Adult, Internal medicine, voriconazole, medicine, MESH : France, Voriconazole, invasive aspergillosis, business.industry, MESH : Drug Therapy, Combination, Galactose, MESH: Male, MESH: Prospective Studies, MESH: France, Transplantation, MESH: Drug Therapy, Combination, MESH : Invasive Pulmonary Aspergillosis, Caspofungin, business, MESH : Mannans, MESH: Seasons
Abstract

International audience; A prospective (2005-2007) hospital-based multicentre surveillance of EORTC/MSG-proven or probable invasive aspergillosis (IA) cases whatever the underlying diseases was implemented in 12 French academic hospitals. Admissions per hospital and transplantation procedures were obtained. Cox regression models were used to determine risk factors associated with the 12-week overall mortality. With 424 case-patients included, the median incidence/hospital was 0.271/10(3) admissions (range 0.072-0.910) without significant alteration of incidence and seasonality over time. Among the 393 adults (62% men, 56 years (16-84 years)), 15% had proven IA, 78% haematological conditions, and 92.9% had lung involvement. Acute leukaemia (34.6%) and allogeneic stem cell transplantation (21.4%) were major host factors, together with chronic lymphoproliferative disorders (21.6%), which emerged as a new high-risk group. The other risk host factors consisted of solid organ transplantation (8.7%), solid tumours (4.3%), systemic inflammatory diseases (4.6%) and chronic respiratory diseases (2.3%). Serum galactomannan tests were more often positive (≥69%) for acute leukaemia and allogeneic stem cell transplantation than for the others (

Published
2011

17. Sex differences in the GSK3β-mediated survival of adherent leukemic progenitors

Author

Jessica Bertrand, Bernard Payrastre, N Gallay, Nathalie Vergnolle, Véronique Maguer-Satta, Mathieu Despeaux, Cécile Demur, Ezzeddine Bourogaa, S Joly, P Bonnevialle, F Louache, Claire Racaud-Sultan, ANDRA, Laboratoire d'Hématologie [Purpan], Université Paul Sabatier - Toulouse 3 ( UPS ) -CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Equipe 11, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Physiopathologie Toulouse Purpan, Université Paul Sabatier - Toulouse 3 ( UPS ) -IFR30-IFR150-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Departement /u563 : Oncogenèse, Signalisation et Innovation thérapeutique, Université Paul Sabatier - Toulouse 3 ( UPS ) -Institut Claudius Regaud-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Claudius Regaud

Subjects
Male, MESH : Aged, Antigens, CD34, MESH : Blotting, Western, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Glycogen Synthase Kinase 3, 0302 clinical medicine, MESH : Indoles, MESH : Tumor Cells, Cultured, GSK-3, Tumor Cells, Cultured, Protein Phosphatase 2, MESH : GTP-Binding Proteins, Cells, Cultured, MESH: Glycogen Synthase Kinase 3, MESH: Etoposide, Etoposide, MESH: Indoles, MESH : Maleimides, Aged, 80 and over, MESH : Cell Survival, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH: Protein Phosphatase 2, Neoplasm Proteins, MESH: Cell Survival, MESH: Young Adult, 030220 oncology & carcinogenesis, Neoplastic Stem Cells, RNA Interference, MESH: Cells, Cultured, MESH : Protein Phosphatase 2, MESH : Glycogen Synthase Kinase 3, MESH: Antineoplastic Agents, Phytogenic, Blotting, Western, MESH : Young Adult, Receptors, Cell Surface, MESH: Cell Adhesion, 03 medical and health sciences, MESH : Neoplasm Proteins, MESH: Sex Factors, Genetics, MESH: Blotting, Western, Humans, MESH : Middle Aged, MESH: Tumor Cells, Cultured, Progenitor cell, MESH : Aged, 80 and over, Clonogenic assay, education, Molecular Biology, Aged, MESH: Interleukin-3 Receptor alpha Subunit, MESH: Humans, Glycogen Synthase Kinase 3 beta, MESH : Hematopoietic Stem Cells, MESH : Humans, MESH : Leukemia, MESH: Adult, MESH: Antigens, CD34, Protein phosphatase 2, Hematopoietic Stem Cells, MESH: Neoplastic Stem Cells, Immunology, MESH: Female, MESH: Neoplasm Proteins, Cancer Research, Indoles, MESH : Receptors, Cell Surface, MESH : Interleukin-3 Receptor alpha Subunit, MESH : Antineoplastic Agents, Phytogenic, MESH: Hematopoietic Stem Cells, Maleimides, MESH: Aged, 80 and over, MESH : Female, MESH: Maleimides, MESH: Receptors, Cell Surface, MESH: Aged, Leukemia, Myeloid leukemia, MESH : Adult, Middle Aged, medicine.anatomical_structure, MESH : Antigens, CD34, Female, Stem cell, Adult, MESH: GTP-Binding Proteins, Cell Survival, MESH : Male, MESH : Sex Factors, MESH: RNA Interference, Population, Interleukin-3 Receptor alpha Subunit, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Etoposide, Biology, Receptors for Activated C Kinase, Young Adult, MESH : Neoplastic Stem Cells, Sex Factors, GTP-Binding Proteins, MESH: Leukemia, MESH : Cells, Cultured, Cell Adhesion, medicine, 030304 developmental biology, Antineoplastic Agents, Phytogenic, MESH: Male, MESH : Cell Adhesion, Cancer research, Bone marrow, MESH : RNA Interference
Abstract

International audience; Therapeutic resistance of acute myeloid leukemia stem cells, enriched in the CD34(+)38(-)123(+) progenitor population, is supported by extrinsic factors such as the bone marrow niche. Here, we report that when adherent onto fibronectin or osteoblast components, CD34(+)38(-)123(+) progenitors survive through an integrin-dependent activation of glycogen synthase kinase 3β (GSK3β) by serine 9-dephosphorylation. Strikingly, GSK3β-mediated survival was restricted to leukemic progenitors from female patients. GSK3β inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients. In leukemic progenitors from female but not male patients, the scaffolding protein RACK1, activated downstream of α(5)β(1)-integrin engagement, was specifically upregulated and controlled GSK3β activation through the phosphatase protein phosphatase 2A (PP2A). In a mirrored manner, survival of adherent progenitors (CD34(+)38(-)) from male but not female healthy donors was partially dependent on this pathway. We conclude that the GSK3β-dependent survival pathway might be sex-specific in normal immature population and flip-flopped upon leukemogenesis. Taken together, our results strengthen GSK3β as a promising target for leukemic stem cell therapy and reveal gender differences as a new parameter in anti-leukemia therapy.

Published
2011

18. Efficacy of Tube Feeding in Binge-Eating/Vomiting Patients

Author

Marie-Claude Brindisi, Daniel Rigaud, Anne Roblot, Bruno Vergès, Véronique Brayer, Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Service d'endocrinologie et nutrition, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] ( CSGA ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )

Subjects
Pediatrics, Hamilton Anxiety Rating Scale, [ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition, medicine.medical_treatment, Medicine (miscellaneous), Anxiety, Anorexia nervosa, law.invention, MESH : Anxiety, Randomized controlled trial, MESH : Depression, MESH: Vomiting, law, MESH : Vomiting, Bulimia, MESH : Muscle, Skeletal, MESH: Treatment Outcome, media_common, MESH: Muscle, Skeletal, Nutrition and Dietetics, MESH : Bulimia Nervosa, Depression, Bulimia nervosa, Body Fluid Compartments, MESH : Adult, Cognitive behavioral therapy, Eating disorders, Treatment Outcome, MESH: Young Adult, MESH : Cognitive Therapy, MESH : Bulimia, Adult, MESH: Enteral Nutrition, medicine.medical_specialty, MESH: Depression, Vomiting, media_common.quotation_subject, MESH : Young Adult, MESH : Treatment Outcome, behavioral disciplines and activities, Young Adult, Enteral Nutrition, MESH: Body Fluid Compartments, mental disorders, medicine, Humans, MESH : Body Fluid Compartments, MESH: Bulimia, Bulimia Nervosa, Muscle, Skeletal, MESH: Humans, Cognitive Behavioral Therapy, MESH: Anxiety, business.industry, MESH : Humans, MESH: Biological Markers, Beck Depression Inventory, MESH: Quality of Life, MESH: Adult, MESH : Quality of Life, Abstinence, medicine.disease, MESH: Cognitive Therapy, Surgery, MESH : Biological Markers, MESH : Enteral Nutrition, Quality of Life, business, MESH: Bulimia Nervosa, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Biomarkers
Abstract

International audience; BACKGROUND: In many binge-eating/vomiting patients, abstinence could not be obtained from classical treatments. Since the authors showed that tube feeding (TF) reduced such episodes in anorexia nervosa (AN)-hospitalized patients, they carried out a randomized trial on the efficacy of TF plus cognitive behavioral therapy (CBT) vs CBT alone in AN and bulimia nervosa adult outpatients. METHODS: The authors randomly assigned 103 ambulatory patients to receive 16 sessions of CBT alone (n = 51) or CBT plus 2 months of TF (n = 52). The main goal was abstinence of binge-eating/vomiting episodes. Other criteria were gains in fat-free mass and muscle mass improvements in nutrition markers, and quality of life (SF-36 Health Survey), depression (Beck Depression Inventory), and anxiety (Hamilton Anxiety Rating Scale) scores. Evaluations were performed at 1, 2 (end of treatment), 5, 8, and 14 months (analysis of variance). RESULTS: TF patients were rapidly and more frequently abstinent at the end of treatment (2 months) than the CBT patients: 81% vs 29% (P < .001). Fat-free mass, biological markers, depressive state (-58% vs -26%), anxiety (-48% vs -15%), and quality of life (+42% vs +13%) were more improved in the TF group than in the CBT group (P < .05). One year later, more TF patients remained abstinent (68% vs 27%, P = .02); they were less anxious, were less depressed, and had better quality of life than the CBT patients (P < .05). CONCLUSION: TF combined with CBT offered better results than CBT alone.

Published
2011

19. Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey. : Childbearing after HIPEC

Author

Andrea Hayes-Jordan, Paul H. Sugarbaker, Pablo Ortega-Deballon, Pompiliu Piso, Audrey Facy, Naoual Bakrin, Patrick Rat, Edward A. Levine, Olivier Glehen, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Département de chirurgie thoracique et digestive [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Baptist Medical Center, Wake Forest University, University Medical Center of Regensburg, Washington Cancer Institute, MD Anderson Cancer Center, and This work was supported by a grant from the University Hospital of Dijon and the Regional Council of Burgundy 2009.

Subjects
MESH : Mitomycin, MESH : Hyperthermia, Induced, MESH : Antineoplastic Combined Chemotherapy Protocols, Surgical oncology, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, MESH : Pregnancy Complications, Neoplastic, Medicine, MESH : Female, [ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery, Peritoneal Neoplasms, media_common, peritoneal carcinomatosis, MESH : Questionnaires, food and beverages, Intraperitoneal chemotherapy, MESH : Adult, MESH : Survival Rate, Combined Modality Therapy, Survival Rate, Treatment Outcome, Oncology, mesothelioma, Childbearing age, Female, Hyperthermic intraperitoneal chemotherapy, pregnancy, Cytoreductive surgery, Pregnancy Complications, Neoplastic, Adult, medicine.medical_specialty, Adolescent, Mitomycin, media_common.quotation_subject, MESH : International Agencies, MESH : Young Adult, Fertility, MESH : Treatment Outcome, pseudomyxoma, intraperitoneal chemotherapy, Article, MESH : Cisplatin, Young Adult, MESH : Peritoneal Neoplasms, MESH : Adolescent, Humans, HIPEC, business.industry, MESH : Humans, fungi, International survey, International Agencies, MESH : Follow-Up Studies, Hyperthermia, Induced, MESH : Chemotherapy, Cancer, Regional Perfusion, Surgery, childbearing, MESH : Pregnancy, Chemotherapy, Cancer, Regional Perfusion, Cisplatin, MESH : Combined Modality Therapy, business, Follow-Up Studies
Abstract

International audience; BACKGROUND: Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) can improve survival in selected patients with primary or secondary peritoneal malignancies. With the opportunity for long-term survival, questions about the impact of those procedures in fertility in women of childbearing age can be raised. MATERIALS AND METHODS: An international survey was performed among all teams participating in the International Peritoneal Surface Malignancy Group in order to collect data about pregnancies and their outcome in women having undergone previous CRS with adjuvant HIPEC. RESULTS: There were 7 pregnancies reported after CRS and HIPEC in women treated for peritoneal malignancies. All these women conceived spontaneously, most of them within 2 years after the procedure. They delivered most often by vaginal way after an uneventful pregnancy. Their newborns were healthy, except 1 case of congenital diaphragmatic hernia requiring emergent surgery. There were 2 additional uneventful pregnancies reported after the diagnosis of pseudomyxoma peritonei and before CRS and HIPEC, with the support of the medical team. Another woman having undergone oocytes retrieval and embryo cryopreservation prior to the surgery was mother of twins after the procedure via a surrogate mother. CONCLUSION: Childbearing after cytoreductive surgery and heated intraperitoneal chemotherapy is possible in women conserving their genital organs after the procedure. The question of fertility should be considered and discussed in women in reproductive age prior to cytoreductive surgery and heated intraperitoneal chemotherapy. Different options could be offered in this setting. Multidisciplinary decision making involving surgical oncologists and fertility specialists is important.

Published
2011

20. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)

Author

Pierre Bordigoni, Danielle Canioni, Michèle Milili, Nathalie Lambert, Claire Galambrun, Marie Ouachée-Chardin, Filomeen Haerynck, Françoise Le Deist, Despina Moshous, Christelle Lenoir, Stephanie Rigaud, Lionel Galicier, Fabien Touzot, Capucine Picard, Mohamed Hamidou, Hirokazu Kanegane, Ester Mejstrikova, Helen Chapel, Eduardo López-Granados, Stéphane Blanche, Alain Dabadie, Jana Pachlopnik Schmid, Pierre-Simon Rohrlich, Fabian Hauck, Geneviève de Saint Basile, Claudin Schiff, Jean-Louis Stephan, Alain Fischer, Isabelle Pellier, Nizar Mahlaoui, Sylvain Latour, Alain Fourmaintraux, Vincent Barlogis, IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'anatomie pathologique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Graduate School of Medicine, University of Toyama, Department of pediatrics, University of Oxford [Oxford], Teaching Hospital Motol and 2nd Medical School, Charles University, Department of Pediatric Hematology and Oncology, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Hématologie pédiatrique, Hôpital de la Timone, Marseille, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Groupe Hospitalier Sud Réunion (GHSR), Centre Hospitalier Universitaire [Rennes], Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Department of Paediatric Pulmonology, Ghent University Hospital, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Département de pédiatrie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, CHU Saint-Etienne, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'étude des Déficits Immunitaires, Assistance Publique-Hôpitaux de Paris, Service d'Immunologie et d'Hématologie Pédiatrique, Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), University of Oxford, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Collège de France - Chaire Médecine expérimentale (A. Fischer), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), IFR Necker-Enfants Malades ( IRNEM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Groupe Hospitalier Sud Réunion ( GHSR ), Centre de Référence Déficits Immunitaires Héréditaires ( CEREDIH ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Centre d'Immunologie de Marseille - Luminy ( CIML ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Génétique Humaine des Maladies Infectieuses ( Inserm U980 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), and Assistance publique - Hôpitaux de Paris (AP-HP)

Subjects
Male, MESH : Retrospective Studies, MESH: X-Linked Inhibitor of Apoptosis Protein, MESH : Aged, MESH : Child, Preschool, Biochemistry, Cohort Studies, Immunoenzyme Techniques, Hypogammaglobulinemia, MESH: Lymphoproliferative Disorders, 0302 clinical medicine, MESH : Child, MESH: Child, hemic and lymphatic diseases, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, XIAP Deficiency, Signaling Lymphocytic Activation Molecule Associated Protein, X-Linked Lymphoproliferative Syndrome, Child, MESH: Cohort Studies, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH : Lymphoproliferative Disorders, Intracellular Signaling Peptides and Proteins, MESH : Infant, Hematology, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH: Infant, 3. Good health, Survival Rate, MESH : Phenotype, Phenotype, MESH: Young Adult, Child, Preschool, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH : Mutation, Adult, medicine.medical_specialty, MESH: Mutation, Adolescent, MESH: Survival Rate, MESH : Male, Immunology, MESH : Young Adult, MESH : Cohort Studies, X-Linked Inhibitor of Apoptosis Protein, Biology, MESH: Phenotype, Virus, Young Adult, 03 medical and health sciences, MESH : Intracellular Signaling Peptides and Proteins, MESH : Immunoenzyme Techniques, MESH : Adolescent, MESH: Intracellular Signaling Peptides and Proteins, medicine, Humans, MESH : Middle Aged, MESH: Immunoenzyme Techniques, Aged, Retrospective Studies, 030304 developmental biology, MESH: Adolescent, Hemophagocytic lymphohistiocytosis, Cytopenia, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Infant, X-linked lymphoproliferative disease, MESH: Adult, MESH: Retrospective Studies, Cell Biology, medicine.disease, Lymphoproliferative Disorders, MESH: Male, MESH : X-Linked Inhibitor of Apoptosis Protein, Mutation, Histopathology, MESH: Female, 030215 immunology
Abstract

X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions.

Published
2011

21. Adaptive Differentiation ofPlasmodium falciparumPopulations Inferred from Single‐Nucleotide Polymorphisms (SNPs) Conferring Drug Resistance and from Neutral SNPs

Author

Rabia Mazmouz, Agnès Aubouy, Emmanuelle Renard, Sabah A. Omar, Jérôme Clain, Sarah Falcão, Emeline Broussier, Abdoulaye Djimde, Vély Jean-François, Jean-François Lepère, Jacques Le Bras, Dorina G. Bustos, Oumou Maïga-Ascofaré, Milijaona Randrianarivelojosia, Mère et enfant face aux infections tropicales (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD) - Université Paris Descartes - Paris 5 (UPD5), Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy, and Odontostomatology, Université de Bamako, Centre de consultations de Bandraboua, Research Institute for Tropical Medicine, Institut Pasteur de Madagascar, Institut Pasteur de Madagascar - Réseau International des Instituts Pasteur (RIIP), Kenya Medical Research Institute, Unité de Recherche 010, IRD, Service National de Lutte Antipaludique, Financial support: French Ministry of Health (grant to the Centre National de Réference du Paludisme), Institut de Médecine et d'Epidémiologie Appliquée/Fondation Léon Mba (grant 5988CLN90PFGO), French Ministry of Foreign Affairs for the France-Philippine Technical Cooperation Project on Malaria (grant), Bio-MalPar Network of Excellence., Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Réseau International des Instituts Pasteur (RIIP), and Kenya Medical Research Institute (KEMRI)

Subjects
Male, MESH: Philippines, MESH: Geography, Philippines, [SDV]Life Sciences [q-bio], Genes, Protozoan, Adaptation, Biological, Drug Resistance, MESH : Aged, Drug resistance, MESH: Africa, MESH : Child, Preschool, MESH : Malaria, Falciparum, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Child, Polymorphism (computer science), MESH: Child, MESH : Haiti, MESH : Philippines, MESH : Plasmodium falciparum, Immunology and Allergy, MESH : Female, MESH : Adaptation, Biological, Malaria, Falciparum, Child, MESH : DNA, Protozoan, MESH: Plasmodium falciparum, Aged, 80 and over, MESH: Aged, Genetics, 0303 health sciences, MESH: Middle Aged, Geography, biology, MESH: Polymorphism, Single Nucleotide, MESH: Malaria, Falciparum, MESH: Infant, Newborn, MESH : Polymorphism, Single Nucleotide, MESH : Geography, MESH : Infant, Middle Aged, MESH : Adult, MESH: Infant, 3. Good health, [SDV] Life Sciences [q-bio], MESH: Haiti, Infectious Diseases, MESH: Genes, Protozoan, MESH: Young Adult, Child, Preschool, MESH : Genes, Protozoan, MESH: Drug Resistance, Female, Adult, Adolescent, MESH : Africa, MESH : Male, Plasmodium falciparum, 030231 tropical medicine, MESH : Young Adult, MESH: DNA, Protozoan, Context (language use), Single-nucleotide polymorphism, MESH : Infant, Newborn, Polymorphism, Single Nucleotide, Young Adult, 03 medical and health sciences, MESH : Adolescent, parasitic diseases, Humans, MESH : Middle Aged, Allele, MESH : Aged, 80 and over, Gene, Allele frequency, Aged, 030304 developmental biology, MESH: Adolescent, MESH : Drug Resistance, MESH: Humans, MESH: Adaptation, Biological, MESH: Child, Preschool, MESH : Humans, Infant, Newborn, Infant, MESH: Adult, DNA, Protozoan, biology.organism_classification, Haiti, MESH: Male, Africa, MESH: Female
Abstract

International audience; BACKGROUND: Theoretical and experimental data support the geographic differentiation strategy as a valuable tool for detecting loci under selection. In the context of Plasmodium falciparum malaria, few populations have been studied, with limited genomic coverage. METHODS: We examined geographic differentiation in P. falciparum populations on the basis of 12 single-nucleotide polymorphisms (SNPs) in 4 genes encoding drug resistance determinants, 5 SNPs in 2 genes encoding antigens, and a set of 17 putatively neutral SNPs dispersed on 13 chromosomes. We sampled 326 parasite isolates representing 7 P. falciparum populations from regions with varied levels of malaria transmission (Gabon, Kenya, Madagascar, Mali, Mayotte, Haiti, and the Philippines). RESULTS: Frequencies of drug resistance alleles varied considerably among populations (mean F(ST), 0.52). In contrast, allele frequencies varied significantly less for antigenic and neutral SNPs (mean F(ST), 0.16 and 0.24, respectively). This contrasting pattern was more pronounced when only the African populations were considered. Signature of selection was detected for most of the resistant SNPs but not for the antigenic SNPs. CONCLUSION: These data further validate the utility of geographic differentiation for identifying loci under strong positive selection, such as drug resistance loci. This study also provides frequencies of molecular makers of resistance in some overlooked populations.

Published
2010

22. Comparison of Early CD4 T-Cell Count in HIV-1 Seroconverters in Côte d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts

Author

Karen Malateste, Xavier Anglaret, Faroudy Boufassa, Christine Rouzioux, Albert Minga, Rodolphe Thiébaut, Charlotte Lewden, Rémonie Seng, André Inwoley, Ali Coulibaly, Thomas Dʼaquin Toni, Laurence Meyer, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Santé reproductive, sexualité, infection à VIH - épidémiologie, démographie, sciences sociales, Institut national d'études démographiques ( INED ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Programme PAC-CI, ANRS, Supported by Agence Nationale de Recherches sur le Sida et les Hépatites Virales., Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut national d'études démographiques (INED)-Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), ANRS France Recherche Nord & sud Sida-hiv hépatites, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Mouillet, Evelyne

Subjects
MESH: CD4 Lymphocyte Count, CD4 cell count, HIV Infections, Cohort Studies, MESH: HIV-1, 0302 clinical medicine, Immunopathology, HIV Seropositivity, Pharmacology (medical), 030212 general & internal medicine, Sida, MESH: Cohort Studies, 0303 health sciences, biology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Liter, MESH: HIV Infections, MESH : Adult, resourcelimited setting, 3. Good health, Infectious Diseases, MESH: Young Adult, Lentivirus, France, Viral disease, Viral load, MESH : HIV-1, Adult, medicine.medical_specialty, MESH: Cote d'Ivoire, MESH : Young Adult, MESH : Cohort Studies, Young Adult, 03 medical and health sciences, MESH: HIV Seropositivity, Acquired immunodeficiency syndrome (AIDS), Internal medicine, MESH : CD4 Lymphocyte Count, MESH : HIV Infections, medicine, Humans, MESH : HIV Seropositivity, Seroconversion, MESH : France, seroconversion, 030304 developmental biology, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH : Cote d'Ivoire, HIV infection, biology.organism_classification, medicine.disease, CD4 Lymphocyte Count, MESH: France, Cote d'Ivoire, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Africa, Immunology, HIV-1, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

International audience; OBJECTIVE: We compared CD4+ decline among untreated HIV-1-infected seroconverters living in Côte d'Ivoire (CI) and in France. METHODS: HIV-1-infected adults were enrolled in the ANRS1220 PRIMO-CI (CI, 1997-2006) and ANRSCO2 SEROCO (France, 1988-1995) cohorts. CD4+ count and percentage declines were estimated from enrollment until 24 months of seroconversion by linear random-effect models adjusted for time since seroconversion, age, gender, cell-associated HIV DNA, HIV RNA, and country. RESULTS: Overall 521 seroconverters (CI 148, 62% men; France 373, 77% men) were enrolled after a median of 7.6 months since seroconversion. Median follow-up duration was 12.7 months. Median age was 28 years. Median baseline CD4+ count was 472 and 560 cells per cubic millimeter, respectively. Median baseline HIV RNA was 4.4 and 4.0 log10 copies per milliliter and median HIV DNA was 3.0 and 2.8 log10 copies per 10(6) peripheral blood mononuclear cells, respectively. In adjusted models, CD4+ count and percentage at baseline were lower in CI than in France (P < 0.01), and the difference did not vary during follow-up (P = 0.55). Low HIV RNA and low HIV DNA at baseline were associated with higher CD4+ count at baseline. CONCLUSIONS: CD4+ count and percentage were lower in CI than in France. These differences were already observed during early infection and remained similar after adjustment.

Published
2010

23. Self-rated residual symptoms do not predict 1-year recurrence of depression

Author

Guido Bondolfi, D. Marra, Jean-Michel Aubry, Christian Osiek, Nicola Gérard Gervasoni, Gilles Bertschy, Marianne Gex-Fabry, Emmanuel Haffen, Laboratoire de Neurosciences Intégratives et Cliniques - UFC ( NEURO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Male, Time Factors, Psychometrics, MESH : Recurrence, MESH : Aged, Test validity, ddc:616.89, 0302 clinical medicine, Recurrence, Surveys and Questionnaires, Depressive Disorder, Major/*diagnosis/*epidemiology, MESH : Female, Major depressive episode, Depression (differential diagnoses), MESH: Aged, MESH: Middle Aged, Questionnaires, MESH : Questionnaires, MESH: Follow-Up Studies, Middle Aged, MESH : Adult, MESH: Predictive Value of Tests, Psychiatry and Mental health, Convergent validity, MESH: Young Adult, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, medicine.symptom, Psychology, MESH : Depressive Disorder, Major, MESH : Time Factors, Adult, Predictive validity, medicine.medical_specialty, MESH : Male, MESH: Depressive Disorder, Major, MESH : Young Adult, Young Adult, 03 medical and health sciences, Predictive Value of Tests, Rating scale, Internal medicine, medicine, Humans, MESH : Middle Aged, MESH : Predictive Value of Tests, Risk factor, Psychiatry, Aged, Depressive Disorder, Major, MESH: Humans, MESH: Questionnaires, MESH: Time Factors, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, MESH: Male, MESH: Recurrence, 030227 psychiatry, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH: Female, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

BackgroundResidual depressive symptoms are generally documented as a risk factor for recurrence. In the absence of a specific instrument for the assessment of residual symptoms, a new 25-item Depression Residual Symptom Scale (DRSS) was elaborated and tested for recurrence prediction over a 1-year follow-up.Sampling and methodsFifty-nine patients in remission after a major depressive episode (MDE) were recruited in two centres. They were assessed with the DRSS and the Montgomery-Asberg Depression Rating Scale (MADRS) at inclusion and followed for 1 year according to a seminaturalistic design. The DRSS included specific depressive symptoms and subjective symptoms of vulnerability, lack of return to usual self and premorbid level of functioning.ResultsSeverity of residual symptoms was not significantly associated with increased risk of recurrence. However, DRSS score was significantly higher among patients with three or more episodes than one to two episodes. Number of previous episodes and treatment interruption were not identified as significant predictors of recurrence.ConclusionThe proposed instrument is not predictive of depressive recurrence, but is sensitive to increased perception of vulnerability associated with consecutive episodes. Limitations include small sample size, seminaturalistic design (no standardisation of treatment) and content of the instrument.

Published
2010

24. Detection of alpha- and beta-human papillomavirus (HPV) in cutaneous melanoma: a matched and controlled study using specific multiplex PCR combined with DNA microarray primer extension

Author

Jean Luc Prétet, Bernadette Kantelip, Christiane Mougin, Tarik Gheit, Jean Baptiste Ruer, Line Pépin, François Aubin, Chrystelle Vidal, Massimo Tommasino, Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Université Libre de Bruxelles [Bruxelles] ( ULB ), Service d'Anatomie pathologique [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Université libre de Bruxelles (ULB)

Subjects
Male, Oncology, Skin Neoplasms, Microarray, Gammapapillomavirus, MESH : Aged, MESH : Gammapapillomavirus, Alphapapillomavirus, Polymerase Chain Reaction, Biochemistry, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Alphapapillomavirus, MESH : Neoplasm Staging, MESH : Female, MESH : DNA, Viral, Melanoma, MESH : Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Skin, MESH: Human papillomavirus 16, Aged, 80 and over, MESH: Aged, Human papillomavirus 16, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, HPV infection, virus diseases, MESH: Neoplasm Staging, Middle Aged, MESH : Adult, Prognosis, female genital diseases and pregnancy complications, 3. Good health, MESH : Oligonucleotide Array Sequence Analysis, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, MESH: Melanoma, MESH : Male, Population, MESH : Melanoma, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Biology, MESH: Betapapillomavirus, MESH: Prognosis, Young Adult, 03 medical and health sciences, MESH: Skin, Internal medicine, Multiplex polymerase chain reaction, MESH : Skin, medicine, Betapapillomavirus, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, education, MESH: Alphapapillomavirus, Molecular Biology, Aged, Neoplasm Staging, 030304 developmental biology, MESH: Humans, MESH : Betapapillomavirus, MESH: Skin Neoplasms, MESH : Skin Neoplasms, MESH : Humans, MESH : Human papillomavirus 16, Cancer, MESH: Adult, MESH: Polymerase Chain Reaction, medicine.disease, DNA extraction, MESH: Male, MESH: DNA, Viral, DNA, Viral, MESH: Oligonucleotide Array Sequence Analysis, Cutaneous melanoma, Immunology, MESH: Female, MESH: Gammapapillomavirus
Abstract

International audience; There are few contradictory studies investigating the involvement of HPV in melanoma. We designed a controlled study to evaluate the HPV DNA prevalence in melanoma. One hundred patients with cutaneous malignant melanoma diagnosed between 2002 and 2006 were included. Complementary wide excision (healthy skin) was performed in 85 patients and was used as internal control. After DNA extraction, 68 different HPV types were studied using a multiplex PCR combined with microarray primer extension. We did not observe any statistical significant difference in terms of HPV DNA prevalence in melanoma (38.8%) and in healthy skin from wide excision (42.4%). Twenty-one different HPV types were detected but only one type was present in the majority of our samples (80/85 melanoma vs 59/66 HS). The distribution of HPV genera and types was similar in melanoma and HS, and beta-HPV was predominant (30.6% and 31.8%). Among alpha-HPV (10.6%), high-risk mucosal HPV16 was predominant. Among beta-HPV, melanoma harboured significantly more type 22 than control normal skin from the same patients and significantly less type 21 than paired control normal skin. No correlation between clinical and pathological melanoma characteristics and HPV DNA prevalence was found. Our data do not support a role of HPV infection in melanocarcinogenesis, but confirm the previous data suggesting that HPV DNA is widely distributed among the population and that occult HPV infections are frequent. Furthermore, specific HPV types, such as a-HPV16 and beta-HPV species 2 may be involved in a sub-group of melanoma.

Published
2009

25. Couples, PMTCT programs and infant feeding decision-making in Ivory Coast

Author

Madina Querre, Valériane Leroy, Annabel Desgrées-du-Loû, Hermann Brou, Alice Desclaux, Annick Tijou Traoré, Aménagement, Développement, Environnement, Santé et Sociétés ( ADES ), Université Bordeaux Segalen - Bordeaux 2-Université Bordeaux Montaigne-Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche Cultures, Santé, Sociétés (JE 2424) ( CReCSS ), Université Paul Cézanne - Aix-Marseille 3-JE2424, Ecole nationale supérieure de statistique et d'économie appliquée [Abidjan] ( ENSEA ), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre population et développement ( CEPED - UMR_D 196 ), Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ), Aménagement, Développement, Environnement, Santé et Sociétés (ADES), Université Bordeaux Segalen - Bordeaux 2-Université Bordeaux Montaigne (UBM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Cultures, Santé, Sociétés (JE 2424) (CReCSS), Ecole nationale supérieure de statistique et d'économie appliquée [Abidjan] (ENSEA), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Centre National de la Recherche Scientifique (CNRS)-Université Bordeaux Segalen - Bordeaux 2-Université Bordeaux Montaigne, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Université Bordeaux Segalen - Bordeaux 2, Université Bordeaux Segalen - Bordeaux 2-Université Bordeaux Montaigne-Centre National de la Recherche Scientifique (CNRS), and Mouillet, Evelyne

Subjects
Male, MESH: Decision Making, Health (social science), MESH : Infant Nutritional Physiological Phenomena, HIV Infections, 0302 clinical medicine, ACTION SANITAIRE, Medicine, education.field_of_study, MESH: Middle Aged, SIDA, COUPLE, MESH: Sex Distribution, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: HIV Infections, MESH: Interviews as Topic, MESH: Infant, Project team, 3. Good health, Breast Feeding, ENFANT, SANTE DE LA REPRODUCTION, MESH: Young Adult, Spouse, MESH: Breast Feeding, MESH: Truth Disclosure, 0305 other medical science, Attitude to Health, medicine.medical_specialty, MESH: Cote d'Ivoire, MESH: Attitude to Health, MESH : Young Adult, Developing country, Truth Disclosure, Feeding Methods, 03 medical and health sciences, History and Philosophy of Science, MESH : HIV Infections, Humans, Interpersonal Relations, MESH : Middle Aged, education, MESH: Age Distribution, MESH: Humans, Public health, MESH : Humans, Infant, MESH : Feeding Methods, ALLAITEMENT MATERNEL, MESH: Adult, PREVENTION SANITAIRE, medicine.disease, Infectious Disease Transmission, Vertical, MESH : Attitude to Health, MESH : Interviews as Topic, MESH : Breast Feeding, ENQUETE, MESH: Female, Pediatrics, TRANSMISSION MERE ENFANT, MESH: Infant Nutritional Physiological Phenomena, MESH : Age Distribution, Breastfeeding, MESH : Interpersonal Relations, 5. Gender equality, MESH : Socioeconomic Factors, MESH : Female, 030212 general & internal medicine, Infant Nutritional Physiological Phenomena, MESH : Infectious Disease Transmission, Vertical, MESH : Sex Distribution, Family Characteristics, MESH: Feeding Methods, Middle Aged, MESH: Interpersonal Relations, MESH : Adult, MESH : Truth Disclosure, MESH: Infectious Disease Transmission, Vertical, Female, Adult, MESH: Socioeconomic Factors, TRANSMISSION, MESH : Male, Decision Making, Population, Interviews as Topic, SYSTEME DE REPRESENTATIONS, Young Adult, Age Distribution, Acquired immunodeficiency syndrome (AIDS), MESH: Family Characteristics, Sex Distribution, MESH : Family Characteristics, 030505 public health, business.industry, PARENT, MESH : Cote d'Ivoire, MESH: Male, MESH : Decision Making, Cote d'Ivoire, Socioeconomic Factors, FEMME, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Family medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Breast feeding
Abstract

International audience; In Sub-Saharan Africa, prevention of HIV pediatric infection due to breastfeeding requires turning to alternatives to prolonged breastfeeding: artificial feeding or exclusive breastfeeding with early weaning. Choosing a preventive option and applying it does not only depend upon the mother but also on the father and more specifically on couple interactions. To date, not enough studies have considered this question. In Abidjan, Ivory Coast, HIV-positive women and their infants were followed over two years in Ditrame Plus, a prevention of mother-to-child transmission (PMTCT) project. Using data from this project and from interviews conducted with couples and women, we analyzed the construction of decisions and practices concerning the application of preventive infant feeding options. Differences may be found between women and men in discourses regarding their attitudes, which are in part related to their conceptions of motherhood and fatherhood. We found that when men know their wife is HIV positive and are involved in the PMTCT project, they play an active role in applying the advice received. However, women do not always need the support of their spouse to undertake preventative behaviour. The project team also plays an important role in the adoption of such by women and men. The implementation of preventive options is a complex process in which three groups of actors (women, men and the project team) interact. In order to optimize PMTCT programs for couples, it is essential that this dynamic be taken into account.

Published
2009

26. TP53 codon 72 polymorphism and cervical cancer

Author

R.J. Pegoraro, Annarosa Del Mistro, M. Pillai, Dhananjaya Saranath, Angel Suarez-Rincon, Joseph Menczer, Adam N. Rosenthal, Giovanni Rezza, Åslaug Helland, Theodoros Agorastos, Virginia M. Schmitt, Maria Blettner, Mark H. Stoler, Jae Weon Kim, Stefanie J. Klug, Ming-Tsang Wu, Sylvia M. F. Brenna, Margaret M. Madeleine, Andrea L. Haws, Peter J.F. Snijders, Wannapa Settheetham-Ishida, Meike Ressing, Martín Carlos Abba, Aleksandra Dybikowska, Marco Ciotti, Tsuyoshi Yamashita, Masatsugu Ueda, Gulielmina Ranzani, Magnus von Knebel Doeberitz, Zivile Gudleviciene, Sun H. Jee, Alan Hildesheim, Hextan Y.S. Ngan, Ate G.J. van der Zee, Krisztina Szarka, Sharmila Sengupta, Ulf Gyllensten, Anna R. Giuliano, Yoshimitsu Niwa, Hiroshi Shirasawa, Ruth Tachezy, Susanta Roychoudhury, Olivier Humbey, Akira Nishikawa, C. Simon Herrington, Ingeborg Zehbe, Jochem Koenig, B. R. Das, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Targeted Gynaecologic Oncology (TARGON), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Pathology, and CCA - Oncogenesis

Subjects
Arginine, MESH : Polymorphism, Genetic, MESH: Genes, p53, MESH : Aged, Physiology, Uterine Cervical Neoplasms, MESH: Papillomavirus Infections, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Genotype, MESH : Female, Cervical cancer, Genetics, MESH: Aged, MESH : Papillomavirus Infections, 0303 health sciences, MESH: Middle Aged, HPV infection, MESH: Genetic Predisposition to Disease, Middle Aged, MESH : Adult, WILD-TYPE P53, Hardy–Weinberg principle, 3. Good health, MESH: Uterine Cervical Neoplasms, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Meta-analysis, Female, Adult, Adolescent, MESH : Uterine Cervical Neoplasms, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Genes, p53, 03 medical and health sciences, Young Adult, SQUAMOUS INTRAEPITHELIAL LESIONS, MESH : Adolescent, INDIAN WOMEN, MESH: Polymorphism, Genetic, medicine, Humans, Genetic Predisposition to Disease, MESH : Middle Aged, Allele, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, Polymorphism, Genetic, HUMAN-PAPILLOMAVIRUS TYPE-16, business.industry, P53 ARG72PRO POLYMORPHISM, HEALTHY WOMEN, Papillomavirus Infections, MESH : Humans, MESH: Adult, Odds ratio, medicine.disease, Genes, p53, GENOTYPES, HARDY-WEINBERG EQUILIBRIUM, RISK-FACTORS, MESH : Genetic Predisposition to Disease, business, MESH: Female, HPV INFECTION
Abstract

Background Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.Methods Individual data on 7946 cases and 7888 controls from 49 different studies worldwide were reanalysed. Odds ratios (OR) were estimated using logistic regression, stratifying by study and ethnic origin. Subgroup analyses were done for infection with HPV, ethnic origin, Hardy-Weinberg equilibrium, study quality, and the material used to determine TP53 genotype.Findings The pooled estimates (OR) for invasive cervical cancer were 1.22 (95% CI 1.08-1-39) for arginine homozygotes compared with heterozygotes, and 1.13 (0.94-1.35) for arginine homozygotes versus proline homozygotes. Subgroup analyses showed significant excess risks only in studies where controls were not in Hardy-Weinberg equilibrium (1.71 [1.21-2.42] for arginine homozygotes compared with heterozygotes), in non-epidemiological studies (1.35 [1.15-1.58] for arginine homozygotes compared with heterozygotes), and in studies where TP53 genotype was determined from tumour tissue (1.39 [1.13-1.73] for arginine homozygotes compared with heterozygotes). Null results were noted in studies with sound epidemiological design and conduct (1.06 [0.87-1.29] for arginine homozygotes compared with heterozygotes), and studies in which TP53 genotype was determined from white blood cells (1.06 [0.87-1.29] for arginine homozygotes compared with heterozygotes).Interpretation Subgroup analyses indicated that excess risks were most likely not due to clinical or biological factors, but to errors in study methods. No association was found between cervical cancer and TP53 codon 72 polymorphism when the analysis was restricted to methodologically sound studies.Funding German Research Foundation (DFG).

Published
2009

27. Multiple tumours in survival estimates

Author

Stefano Guzzinati, Florence Molinié, Rafael Marcos-Gragera, Eva Ardanaz, Tiziana Cassetti, Angel Izquierdo Font, Milena Sant, Stanislaw Gozdz, Rafael Peris-Bonet, Pascale Grosclaude, Emmanuel Desandes, Michel Coleman, Laura Ciccolallo, Lucia Mangone, Freddie Bray, Hermann Brenner, Giovanna Tagliabue, Mariano Santaquilani, Enrico Grande, Maria Zwierko, Jan Willem Coebergh, Emanuele Crocetti, Giulia Zigon, Roberta De Angelis, Stefano Ferretti, Andrea Tavilla, Gemma Gatta, Silvia Francisci, Paolo Contiero, Rosario Tumino, Laufey Tryggvadottir, Franco Berrino, Hans Storm, Paolo Baili, David Brewster, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Evaluative Epidemiology Unit, Fondazione IRCCS, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Neurology, and Public Health

Subjects
Male, Oncology, Cancer Research, Survival, MESH : Age Distribution, MESH : Aged, MESH : Neoplasms, Multiple Primary, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Neoplasms, Multiple Primary, MESH: Aged, 80 and over, 0302 clinical medicine, Multiple Primary, Prostate, Neoplasms, Epidemiology, 80 and over, Cancer registries, MESH: Neoplasms, Multiple Primary, MESH : Female, 030212 general & internal medicine, Young adult, 10. No inequality, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Relative survival, Medicine (all), MESH: Sex Distribution, Multiple tumours, Neoplasm, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Middle Aged, Sex Distribution, Survival Analysis, Young Adult, Percentage point, MESH : Adult, 3. Good health, Multiple tumours - survival estimates, medicine.anatomical_structure, MESH: Young Adult, MESH: Survival Analysis, 030220 oncology & carcinogenesis, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH: Male, Surgery, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

In international comparisons of cancer registry based survival it is common practice to restrict the analysis to first primary tumours and exclude multiple cancers. The probability of correctly detecting subsequent cancers depends on the registry's running time, which results in different proportions of excluded patients and may lead to biased comparisons. We evaluated the impact on the age-standardised relative survival estimates of also including multiple primary tumours. Data from 2,919,023 malignant cancers from 69 European cancer registries participating in the EUROCARE-4 collaborative study were used. A total of 183,683 multiple primary tumours were found, with an overall proportion of 6.3% over all the considered cancers, ranging from 0.4% (Naples, Italy) to 12.9% (Iceland). The proportion of multiple tumours varied greatly by type of tumour, being higher for those with high incidence and long survival (breast, prostate and colon-rectum). Five-year relative survival was lower when including patients with multiple cancers. For all cancers combined the average difference was -0.4 percentage points in women and -0.7 percentage points in men, and was greater for older registries. Inclusion of multiple tumours led to lower survival in 44 out of 45 cancer sites analysed, with the greatest differences found for larynx (-1.9%), oropharynx (-1.5%), and penis (-1.3%). Including multiple primary tumours in survival estimates for international comparison is advisable because it reduces the bias due to different observation periods, age, registration quality and completeness of registration. The general effect of inclusion is to reduce survival estimates by a variable amount depending on the proportion of multiple primaries and cancer site. (C) 2008 Elsevier Ltd. All rights reserved.

Published
2009

28. The advantage of women in cancer survival: An analysis of EUROCARE-4 data

Author

Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health

Subjects
Oncology, Male, Pathology, Cancer Research, cancer survival - women, MESH : Age Distribution, MESH : Aged, MESH: Risk Assessment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Neoplasms, 80 and over, Gender differences, Sex hormones, MESH: Neoplasms, MESH : Female, MESH: Residence Characteristics, Young adult, Age of Onset, MESH : Risk Assessment, MESH : Sex Distribution, MESH: Diagnosis-Related Groups, MESH: Aged, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Thyroid, MESH: Sex Distribution, Middle Aged, MESH : Adult, 3. Good health, MESH : Age of Onset, Europe, MESH : Diagnosis-Related Groups, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, Female, EUROCARE, Adult, medicine.medical_specialty, Adolescent, MESH: Age of Onset, MESH : Male, MESH : Sex Factors, Population, MESH : Europe, MESH : Young Adult, Rectum, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, Young Adult, Age Distribution, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Sex Distribution, education, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, Diagnosis-Related Groups, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, Cancer survival, Survival Analysis, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, Age of onset, MESH : Survival Analysis, business, MESH: Female
Abstract

We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.

Published
2009

29. Egocentric reference in bidirectional readers as measured by the straight-ahead pointing task

Author

Sylvie Chokron, Esther Gaash, Eve Dupierrix, Seta Kazandjian, Itamar Y. Love, Ari Z. Zivotofsky, Maria De Agostini, Laboratoire de Psychologie et NeuroCognition (LPNC), Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire Psychologie de la Perception (LPP - UMR 8242), Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Cannard, Christine, Laboratoire de Psychologie et NeuroCognition ( LPNC ), Université Pierre Mendès France - Grenoble 2 ( UPMF ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Psychologie de la Perception ( LPP - UMR 8242 ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Male, Egocentrism, MESH: Proprioception, MESH: Language Tests, First language, MESH : Photic Stimulation, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SCCO.PSYC ] Cognitive science/Psychology, 050109 social psychology, MESH: Observer Variation, MESH : Learning, 0302 clinical medicine, Reading (process), MESH : Female, MESH: Arm, Spatial organization, Language, media_common, Observer Variation, Language Tests, Point (typography), General Neuroscience, 05 social sciences, MESH : Adult, MESH: Ego, MESH: Photic Stimulation, medicine.anatomical_structure, MESH : Proprioception, Motor Skills, MESH: Young Adult, MESH : Motor Skills, MESH: Language, [ SCCO.NEUR ] Cognitive science/Neuroscience, [SCCO.PSYC]Cognitive science/Psychology, Arm, Educational Status, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH : Space Perception, Psychology, Social psychology, MESH : Orientation, Cognitive psychology, Adult, MESH : Male, media_common.quotation_subject, MESH : Language Tests, MESH: Space Perception, MESH : Young Adult, MESH: Orientation, MESH: Psychomotor Performance, MESH : Arm, [SHS.PSY] Humanities and Social Sciences/Psychology, [ SHS.PSY ] Humanities and Social Sciences/Psychology, Young Adult, 03 medical and health sciences, MESH : Verbal Behavior, MESH : Language, Orientation, medicine, Humans, Learning, 0501 psychology and cognitive sciences, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Molecular Biology, Ego, Visual search, MESH: Verbal Behavior, MESH: Humans, Verbal Behavior, [SCCO.NEUR]Cognitive science/Neuroscience, MESH : Humans, MESH: Adult, MESH : Observer Variation, MESH : Psychomotor Performance, Spatial cognition, Proprioception, MESH: Male, Sagittal plane, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Space Perception, MESH: Learning, Neurology (clinical), MESH: Educational Status, MESH: Female, MESH : Educational Status, Photic Stimulation, Psychomotor Performance, 030217 neurology & neurosurgery, MESH : Ego, MESH: Motor Skills, Developmental Biology
Abstract

International audience; The present study aimed to show that bidirectional reading and language exposure influence the position of egocentric reference (ER), the perceived direction of the body's sagittal axis proposed to act as an anchor for movements in extracorporeal space. Directional factors (e.g., visual scanning bias and reading habits) have been proposed to influence visuospatial performance, such as in line bisection and figure drawing. In past studies, bidirectional readers have been less consistent in demonstrating a bias compared to unidirectional readers. Using a straight-ahead pointing task to assess egocentric reference, we compared 14 unidirectional left-to-right readers (Uni-LR) to three bidirectional reading groups that differed in the reading direction of their native language and/or the level of their second language literacy: 16 low-English literate, native right-to-left, bidirectional readers (Lo-Bi-RL), 13 high-English literate, native right-to-left, bidirectional readers (Hi-Bi-RL), and 15 native left-to-right, bidirectional readers (Bi-LR). Participants were asked to point straight-ahead while blindfolded using either a left-to-right or a right-to-left scanning direction to approach the subjective sagittal midline. Uni-LRs showed left-side spatial bias when scanning left-to-right and right-side bias during right-to-left scanning, Bi-LRs and Lo-Bi-RLs (i.e., intermediate level or less in their second language) demonstrated the opposite pattern, and Hi-Bi-RLs showed left-side spatial bias regardless of scanning direction. Results are discussed in terms of accuracy and spatial bias regarding the interaction between reading direction and spatial cognition based on the level of bidirectional literacy and language exposure.

Published
2009

30. Incidence and survival of gastric non-Hodgkin's lymphoma: A population-based study from the Association of the French Cancer Registries (FRANCIM)

Author

Danzon, Arlette, Belot, Aurélien, Maynadié, Marc, Remontet, Laurent, Dupont, Anne Claire Gossart, Carbonnel, Franck, Renseigné, Non, FRANCIM, Réseau des registres français du cancer, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Biostatistique, Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Registre des hémopathies malignes de Côte d'Or, Service de biostatistique, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), and Université de Franche-Comté ( UFC )

Subjects
Male, Multivariate analysis, MESH: Registries, MESH : Age Distribution, MESH : Aged, 0302 clinical medicine, MESH: Lymphoma, Non-Hodgkin, Risk Factors, MESH: Risk Factors, Epidemiology, MESH : Stomach Neoplasms, MESH : Neoplasm Staging, MESH : Female, Registries, MESH: Incidence, 030212 general & internal medicine, Age of Onset, MESH : Sex Distribution, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Relative survival, Incidence, Lymphoma, Non-Hodgkin, Incidence (epidemiology), MESH: Sex Distribution, Not Otherwise Specified, MESH: Stomach Neoplasms, MESH: Neoplasm Staging, Hematology, General Medicine, Middle Aged, MESH : Adult, Prognosis, MESH : Risk Factors, MESH : Incidence, MESH : Age of Onset, 3. Good health, Oncology, MESH: Young Adult, MESH: Survival Analysis, 030220 oncology & carcinogenesis, Female, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, France, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH: Age of Onset, MESH : Young Adult, MESH: Multivariate Analysis, MESH: Prognosis, Young Adult, 03 medical and health sciences, Age Distribution, Stomach Neoplasms, MESH : Adolescent, Internal medicine, medicine, Humans, MESH : Middle Aged, MESH : Lymphoma, Non-Hodgkin, Radiology, Nuclear Medicine and imaging, Sex Distribution, MESH : France, MESH: Age Distribution, Survival analysis, Aged, Neoplasm Staging, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH : Multivariate Analysis, Cancer, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Survival Analysis, MESH: Male, MESH: France, Multivariate Analysis, Immunology, MESH : Survival Analysis, Age of onset, business, MESH: Female, MESH : Registries
Abstract

International audience; BACKGROUND: Most epidemiological studies on gastric lymphomas (GL) were carried out before changes in therapy were introduced. The aim of the study was to measure the incidence of GL and to estimate survival. MATERIAL AND METHODS: Data were provided by the Association of the French Cancer Registries database. Age-standardized incidence rates were calculated for 786 incident cases diagnosed between 1978 and 2002. Crude and relative survival were calculated for 361 cases diagnosed between 1989 and 1997. Effects specific to sex, age at diagnosis, year of diagnosis, and grade of malignancy were estimated in multivariate analysis. RESULTS: Incidence was stable during the study period. However, high-grade GL frequency increased whereas low-grade and not otherwise specified (NOS) GL frequencies were respectively stable and decreased. At 5 years, relative survival was 63% in men and 60% in women. Patients aged 75 or older had a five-year relative survival of 33%. Age at diagnosis was the only significant prognostic factor in multivariate analysis. Time trend improvement in prognosis was observed. DISCUSSION: Results in elderly patients show that therapeutic regimens should be specifically designed and assessed for them. The prognosis improvement trend is probably related to the implementation of changes in management of patients and has to be confirmed by more recent data.

Published
2009

31. Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone

Author

Swerdlow , Anthony, Cooke , Rosie, Albertsson-Wikland , Kerstin, Borgström , Birgit, Butler , Gary, Cianfarani , Stefano, Clayton , Peter, Coste , Joël, Deodati , Annalisa, Ecosse , Emmanuel, Gausche , Ruth, Giacomozzi , Claudio, Kiess , Wieland, Hokken-Koelega , Anita, Kuehni , Claudia, Landier , Fabienne, Maes , Marc, Mullis , Primus-E, Pfaffle , Roland, Sävendahl , Lars, Sommer , Grit, Thomas , Muriel, Tollerfield , Sally, Zandwijken , Gladys, Carel , Jean-Claude, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Unité d'endocrinologie pédiatrique, Institute of Cancer Research - ICR [London, U.K.], Sahlgrenska Academy at University of Gothenburg [Göteborg], Karolinska Institutet [Stockholm], Institute of Child Health [London], University College of London [London] (UCL), University College London Hospitals (UCLH), IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Royal Manchester Children's Hospital, University of Manchester [Manchester], Unité d’Epidémiologie et de Biostatistiques [APHP Cochin-Broca-Hôtel Dieu], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Universität Leipzig [Leipzig], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Sophia Children's Hospital, Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern], Centre de Référence des Maladies Endocriniennes Rares de la Croissance [APHP Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service d'endocrinologie diabétologie pédiatrique [CHU Debré], AP-HP Hôpital universitaire Robert-Debré [Paris], Université Paris Diderot - Paris 7 (UPD7), Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Hopital Robert Debre, Institut National de la Santé et de la Recherche Médicale (INSERM), Cliniques universitaires St Luc [Bruxelles], Inselspital Bern, Belgian Study Group for Pediatric Endocrinology (BSGPE), Universitair Ziekenhuis Brussel, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), University College of London [London] ( UCL ), University College London Hospitals ( UCLH ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Erasmus Medical Center / Dutch Growth Research Foundation, Erasmus University Medical Center [Rotterdam], Institute of Social and Preventive Medicine [Bern] ( ISPM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Université Paris Diderot - Paris 7 ( UPD7 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Belgian Study Group for Pediatric Endocrinology ( BSGPE ), and Pediatrics

Subjects
Male, MESH : Risk, MESH : Child, Preschool, Cohort Studies, MESH: Cause of Death, MESH: Recombinant Proteins, MESH : Child, Cause of Death, Neoplasms, MESH: Child, MESH: Human Growth Hormone, MESH : Female, MESH: Neoplasms, MESH: Incidence, Child, MESH: Cohort Studies, Growth Disorders, Cancer, MESH: Risk, Human Growth Hormone, Incidence, MESH: Infant, Newborn, Cohort, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Follow-Up Studies, MESH: Growth Disorders, MESH: Infant, MESH : Incidence, Recombinant Proteins, Europe, MESH: Young Adult, Child, Preschool, Female, Risk, Adolescent, MESH : Recombinant Proteins, MESH : Male, MESH : Europe, MESH : Young Adult, MESH : Cohort Studies, 610 Medicine & health, MESH : Infant, Newborn, Young Adult, SDG 3 - Good Health and Well-being, 360 Social problems & social services, MESH : Adolescent, Humans, MESH : Growth Disorders, MESH : Human Growth Hormone, Mortality, Growth hormone, MESH : Cause of Death, Settore MED/38 - Pediatria Generale e Specialistica, MESH: Adolescent, Original Paper, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Infant, Newborn, Infant, MESH : Follow-Up Studies, MESH : Neoplasms, MESH: Male, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, MESH: Female, Follow-Up Studies
Abstract

International audience; BACKGROUND:The long-term safety of growth hormone treatment is uncertain. Raised risks of death and certain cancers have been reported inconsistently, based on limited data or short-term follow-up by pharmaceutical companies.PATIENTS AND METHODS:The SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study assembled cohorts of patients treated in childhood with recombinant human growth hormone (r-hGH) in 8 European countries since the first use of this treatment in 1984 and followed them for cause-specific mortality and cancer incidence. Expected rates were obtained from national and local general population data. The cohort consisted of 24,232 patients, most commonly treated for isolated growth failure (53%), Turner syndrome (13%) and growth hormone deficiency linked to neoplasia (12%). This paper describes in detail the study design, methods and data collection and discusses the strengths, biases and weaknesses consequent on this.CONCLUSION:The SAGhE cohort is the largest and longest follow-up cohort study of growth hormone-treated patients with follow-up and analysis independent of industry. It forms a major resource for investigating cancer and mortality risks in r-hGH patients. The interpretation of SAGhE results, however, will need to take account of the methods of cohort assembly and follow-up in each country.

Published
2015

32. Posttraumatic mucormycosis: a nationwide study in France and review of the literature

Author

Emmanuel GYAN, Norbert IFRAH, Stéphane Bretagne, Frédéric GRENOUILLET, Marcio Junior, Sophie Cassaing, Jean-Francois Viel, Bruno MARCHOU, Raoul Herbrecht, Daniel Ajzenberg, Catherine Quantin, Cedric Arvieux, Mikael Hivelin, Stéphane Ranque, Boualem Sendid, Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service de Chirurgie plastique, reconstructrice et esthétique [Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), Service de parasitologie et de mycologie médicales [Amiens], Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Reims (CHU Reims), Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), Laboratoire de parasitologie et de mycologie médicales [CHU Amiens], CHU Amiens-Picardie, Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire ( CNRMA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ), Université de Picardie Jules Verne ( UPJV ) -CHU Amiens-Picardie, Matrice extracellulaire et dynamique cellulaire - UMR 7369 ( MEDyC ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Reims Champagne-Ardenne ( URCA ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ), Centre Hospitalier Universitaire de Reims ( CHU Reims ), Pathogénie des infections systémiques ( UMR_S 570 ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
MESH : Aged, Poison control, MESH: Aged, 80 and over, MESH : Child, MESH: Child, MESH : Female, Young adult, MESH: Aged, MESH: Middle Aged, biology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH : Adult, MESH : Wounds and Injuries, 3. Good health, MESH : Mucorales, MESH: Young Adult, Cohort, Coinfection, MESH: Mucorales, Antifungal, medicine.medical_specialty, medicine.drug_class, MESH : Male, MESH : Young Adult, MESH : Adolescent, Internal medicine, Injury prevention, medicine, MESH : Middle Aged, MESH : Mucormycosis, MESH : France, MESH : Aged, 80 and over, MESH: Mucormycosis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Mucormycosis, MESH: Adult, Saksenaea vasiformis, medicine.disease, biology.organism_classification, MESH: Male, Surgery, MESH: France, MESH: Wounds and Injuries, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female
Abstract

International audience; Data on clinical, mycologic characteristics, and outcome of posttraumatic mucormycosis are scarce and often limited to case reports. From the French nationwide "RetroZygo" study, we compared posttraumatic mucormycosis cases with other forms of mucormycosis. We also reviewed reports of posttraumatic mucormycosis in the English-language literature from 1993 to 2013. We included all proven or probable cases for which underlying condition, route of infection, surgical and antifungal treatments, and outcome were detailed. From our cohort, posttraumatic mucormycosis (n = 16) differed significantly from other forms (n = 85) by rarity of underlying disease (31.2% vs 81%, p

Published
2014

33. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort

Author

Jingbo Niu, Nathalie Rincheval, Bernard Combe, Josefina Durán, David T. Felson, Cécile Gaujoux-Viala, Clinical Epidemiology Research and Training Unit ( BOSTON - Clin Epid Research ), Boston University School, Rheumatology Department ( Rheum Dep - SANTIAGO ), Pontificia Universidad Catolica del Chile, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Department of rheumatology, University of Nimes, Arthritis Research UK Epidemiology Unit ( MANCHESTER - Arthritis Research ), University of Manchester [Manchester], Centre d'Investigation Clinique INSERM 1412 ( CIC 1412 - BREST ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), CHRU Brest - Service de Rhumatologie ( CHU - BREST - Rhumato ), Lymphocyte B et Auto-immunité ( LBAI ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinical Epidemiology Research and Training Unit (BOSTON - Clin Epid Research), Boston University School of Medicine (BUSM), Boston University [Boston] (BU)-Boston University [Boston] (BU), Rheumatology Department (Rheum Dep - SANTIAGO), Pontificia Universidad Católica de Chile (UC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Arthritis Research UK Epidemiology Unit (MANCHESTER - Arthritis Research), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Boston University [Boston] (BU), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, and Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)

Subjects
Male, rheumatoid arthritis, MESH: Remission Induction, MESH: Antirheumatic Agents, MESH : Fibromyalgia, [SDV]Life Sciences [q-bio], early rheumatoid arthritis, MESH : Aged, Arthritis, Severity of Illness Index, DMARDs, Arthritis, Rheumatoid, Cohort Studies, fibromyalgic RA, 0302 clinical medicine, Fibromyalgia, MESH : Female, Pharmacology (medical), 030212 general & internal medicine, Prospective cohort study, skin and connective tissue diseases, MESH: Cohort Studies, ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, MESH: Aged, MESH: Arthritis, Rheumatoid, MESH: Middle Aged, Remission Induction, MESH: Follow-Up Studies, Middle Aged, Clinical Science, MESH : Adult, Corrigenda, MESH : Antirheumatic Agents, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Young Adult, Antirheumatic Agents, Rheumatoid arthritis, Cohort, Female, fibromyalgia, MESH : Severity of Illness Index, Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Young Adult, MESH : Cohort Studies, MESH : Treatment Outcome, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Young Adult, outcome measures, 03 medical and health sciences, Rheumatology, Internal medicine, MESH: Severity of Illness Index, disease activity scores, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, medicine, Humans, MESH : Middle Aged, Aged, MESH: Adolescent, 030203 arthritis & rheumatology, therapy, MESH : Remission Induction, MESH: Fibromyalgia, MESH: Humans, DASS, [ SDV ] Life Sciences [q-bio], Surrogate endpoint, business.industry, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, medicine.disease, Crohn's Disease Activity Index, MESH: Male, MESH : Arthritis, Rheumatoid, Physical therapy, business, treat to target, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract

International audience; OBJECTIVE:To evaluate whether patients with RA who belong to the spectrum of fibromyalgic RA (FRA) have an impaired response to treatment measured by traditional activity scores.METHODS:Patients from the ESPOIR cohort were analysed. This prospective cohort included 813 patients with early arthritis not initially receiving DMARDs. Among the 697 patients who met RA classification criteria, we studied two groups, one with and the other without FRA. The following endpoints were compared at 6, 12 and 18 months using a mixed linear regression model: 28-joint DAS (DAS28), Simple Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and HAQ. In addition, attainment of low disease activity (LDA; DAS28

Published
2017

34. Crimean-Congo hemorrhagic fever serosurvey in at-risk professionals, Madagascar, 2008 and 2009

Author

Soa Fy Andriamandimby, Noël Tordo, Pierre E. Rollin, Jean-Michel Heraud, Jean-Marc Reynes, Jean-Théophile Rafisandratantsoa, Philippe Marianneau, Unité d'Epidémiologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP), Réseau International des Instituts Pasteur (RIIP), Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Institut Pasteur de Madagascar - Réseau International des Instituts Pasteur (RIIP), Biologie des Infections Virales Émergentes (UBIVE), Institut Pasteur [Paris], Viral Special Pathogens Branch, Centers for Disease Control and Prevention - WHO Collaborative Centre for Viral Hemorrhagic Fevers, Stratégies Antivirales, Institut Pasteur [Paris] - Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]

Subjects
Male, Crimean–Congo hemorrhagic fever, MESH : Hemorrhagic Fever Virus, Crimean-Congo, MESH : Aged, Disease, Surveys, Antibodies, Viral, Serology, MESH : Cross-Sectional Studies, 0302 clinical medicine, Seroepidemiologic Studies, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH : Seroepidemiologic Studies, Epidemiology, MESH : Female, At-Risk Population, Aged, 80 and over, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, 0303 health sciences, biology, MESH : Occupational Diseases, Middle Aged, MESH : Adult, MESH : Abattoirs, 3. Good health, Occupational Diseases, [SDV] Life Sciences [q-bio], MESH : Occupational Exposure, Infectious Diseases, Hemorrhagic Fever Virus, Crimean-Congo, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Crimean-Congo hemorrhagic fever, Female, Livestock, Abattoirs, Crimean Congo hemorrhagic fever virus, Adult, MESH : Antibodies, Viral, MESH : Hemorrhagic Fever, Crimean, medicine.medical_specialty, Adolescent, MESH : Madagascar, MESH : Male, 030231 tropical medicine, MESH : Young Adult, Tick, Young Adult, 03 medical and health sciences, Occupational Exposure, MESH : Adolescent, Virology, Environmental health, parasitic diseases, Madagascar, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, 030304 developmental biology, business.industry, MESH : Humans, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, biology.organism_classification, medicine.disease, Cross-Sectional Studies, Hemorrhagic Fever, Crimean, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

International audience; Background: Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic arboviral infection with hemorrhagic manifestation and often a fatal ending. Human become infected mainly through tick bite or by crushing infected tick, by contact with blood or tissues from viraemic livestock or patient. CCHF virus (CCHFV) has been isolated once in Madagascar but data on the epidemiology of the disease in the country are very scarce. Objectives: To investigate the circulation and the geographic distribution of CCHFV infection among at risk population in Madagascar. Study design: A national cross-sectional serologic survey was performed in 2008–2009 among slaughterhouse workers. Results: A total of 1995 workers were included. A recent CCHFV infection was detected in 1 of the 1995 participants (0.5‰; 95% confidence interval [CI]: 0–0.15%), and a past CCHFV infection was detected in 15 participants (0.75%; 95% CI: 0.37–1.13%). Conclusion: Overall, the percentage of CCHFV infection seen in Madagascar among at-risk professionals is very low compared to endemic countries. An assessment of the prevalence in livestock as a sensitive indicator of CCHFV activity must be considered in order to confirm the lack or the weak endemicity of CCHF in Madagascar.

Published
2011

35. APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. : Kidney donation in twins with APOL1 variant

Author

Kofman, Tomek, Audard, Vincent, Narjoz, Céline, Gribouval, Olivier, Matignon, Marie, Leibler, Claire, Desvaux, Dominique, Lang, Philippe, Grimbert, Philippe, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Bases moléculaires de la réponse aux xénobiotiques ( U775 (IFR95) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Néphropathies héréditaires et rein en développement ( UMR_S 983 ), CHU Necker - Enfants Malades [AP-HP]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Assistance publique - Hôpitaux de Paris (AP-HP), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Bases moléculaires de la réponse aux xénobiotiques (U775 (IFR95)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Néphropathies héréditaires et rein en développement (UMR_S 983), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Necker - Enfants Malades [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
MESH : Polymorphism, Genetic, MESH : Male, MESH: Renal Insufficiency, Chronic, MESH : Young Adult, APOL1 polymorphism, kidney transplantation, MESH : Genotype, MESH : Renal Insufficiency, Chronic, MESH: Lipoproteins, HDL, MESH : Diseases in Twins, MESH: Kidney Transplantation, MESH: Genotype, MESH: Biopsy, MESH: Apolipoproteins, MESH: Polymorphism, Genetic, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology, donor, MESH: Living Donors, MESH: Humans, urogenital system, MESH : Humans, MESH: Genetic Predisposition to Disease, MESH : Follow-Up Studies, MESH: Follow-Up Studies, MESH: Kidney, MESH: Male, MESH : Kidney, MESH : Twins, Monozygotic, MESH: Young Adult, MESH : Biopsy, MESH : Living Donors, outcome, MESH : Lipoproteins, HDL, MESH : Kidney Transplantation, MESH : Genetic Predisposition to Disease, MESH: Twins, Monozygotic, MESH: Diseases in Twins, MESH : Apolipoproteins
Abstract

International audience; We report an occurrence of progressive loss of transplant function and ultimately transplant failure after living related kidney transplantation involving monozygotic twin brothers of Afro-Caribbean origin who were both heterozygous for the G1 and G2 kidney disease risk alleles in the APOL1 gene, which encodes apolipoprotein L-I. A 21-year-old man with end-stage kidney disease of unknown cause received a kidney from his brother, who was confirmed as a monozygotic twin by microsatellite analysis. Thirty months after transplantation, the patient presented with proteinuria and decreased estimated glomerular filtration rate; a biopsy of the transplant showed typical focal segmental glomerulosclerosis lesions. He received steroid therapy, but progressed to kidney failure 5 years later. The twin brother had normal kidney function without proteinuria at the time of transplantation; however, 7 years later, he was found to have decreased estimated glomerular filtration rate (40mL/min/1.73m(2)) and proteinuria (protein excretion of 2.5g/d). APOL1 genotyping revealed that both donor and recipient were heterozygous for the G1 and G2 alleles. This case is in stark contrast to the expected course of kidney transplantation in identical twins and suggests a role for APOL1 polymorphisms in both the donor and recipient.

Published
2014

36. Enhancing the cross-cultural adaptation and validation process: linguistic and psychometric testing of the Brazilian-Portuguese version of a self-report measure for dry eye

Author

Epstein, J, Santo, Ruth Miyuki, Ribeiro-Ferreira, Felipe, Alves, Milton Ruiz, Epstein, Jonathan, Novaes, Priscila, Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Escola Paulista de Medicina [São Paulo] (EPM), Universidade de São Paulo (USP), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Escola Paulista de Medicina [São Paulo] ( EPM ), Universidade de São Paulo ( USP ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL )

Subjects
Questionnaires, Male, Longitudinal study, Translation, MESH: Self Report, Epidemiology, Intraclass correlation, MESH : Aged, MESH : Prospective Studies, MESH : Self Report, MESH: Aged, 80 and over, MESH: Health Surveys, Surveys and Questionnaires, MESH: Cross-Cultural Comparison, Content validity, Ocular Surface Disease Index, MESH : Female, Longitudinal Studies, Prospective Studies, MESH: Translations, MESH: Longitudinal Studies, Reliability (statistics), ComputingMilieux_MISCELLANEOUS, Language, MESH : Longitudinal Studies, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, MESH : Psychometrics, MESH : Dry Eye Syndromes, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Middle Aged, Self-report measure, MESH : Portugal, MESH: Reproducibility of Results, MESH: Portugal, MESH: Young Adult, MESH: Language, language, Dry Eye Syndromes, Female, Psychology, MESH : Surveys and Questionnaires, Brazil, Clinical psychology, Cross-Cultural Comparison, MESH : Cross-Cultural Comparison, Adolescent, Psychometrics, MESH : Male, MESH : Young Adult, MESH : Health Surveys, Dry eye, MESH : Translations, Young Adult, Cronbach's alpha, Brazilian Portuguese, MESH: Psychometrics, MESH : Language, MESH : Adolescent, LINGUÍSTICA APLICADA, MESH : Brazil, Humans, MESH : Middle Aged, Translations, MESH: Surveys and Questionnaires, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, MESH : Aged, 80 and over, Aged, MESH: Adolescent, Cross-cultural adaptation, MESH: Humans, Portugal, MESH : Reproducibility of Results, MESH : Humans, Reproducibility of Results, MESH: Dry Eye Syndromes, Guideline, Health Surveys, language.human_language, MESH: Male, MESH: Prospective Studies, Validation studies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Self Report, MESH: Brazil, MESH: Female
Abstract

International audience; OBJECTIVES:To provide a reliable, validated, and culturally adapted instrument that may be used in monitoring dry eye in Brazilian patients and to discuss the strategies for the enhancement of the cross-cultural adaptation and validation process of a self-report measure for dry eye.METHODS:The cross-cultural adaptation process (CCAP) of the original Ocular Surface Disease Index (OSDI) into Brazilian-Portuguese was conducted using a 9-step guideline. The synthesis of translations was tested twice, for face and content validity, by different subjects (focus groups and cognitive interviews). The expert committee contributed on several steps, and back translations were based on the final rather than the prefinal version. For validation, the adapted version was applied in a prospective longitudinal study to 101 patients from the Dry Eye Clinic at the General Hospital of the University of São Paulo, Brazil. Simultaneously to the OSDI, patients answered the short form-36 health survey (SF-36) and the 25-item visual function questionnaire (VFQ-25) and underwent clinical evaluation. Internal consistency, test-retest reliability, and measure validity were assessed.RESULTS:Cronbach's alpha value of the cross-culturally adapted Brazilian-Portuguese version of the OSDI was 0.905, and the intraclass correlation coefficient was 0.801. There was a statistically significant difference between OSDI scores in patients with dry eye (41.15 ± 27.40) and without dry eye (17.88 ± 17.09). There was a negative association between OSDI and VFQ-25 total score (P < 0.01) and between the OSDI and five SF-36 domains. OSDI scores correlated positively with lissamine green and fluorescein staining scores (P < 0.001) and negatively with Schirmer test I and tear break-up time values (P < 0.001).CONCLUSION:Although most of the reviewed guidelines on CCAP involve well-defined steps (translation, synthesis/reconciliation, back translation, expert committee review, pretesting), the proposed methodological steps have not been applied in a uniform way. The translation and adaptation process requires skill, knowledge, experience, and a considerable investment of time to maximize the attainment of semantic, idiomatic, experiential, and conceptual equivalence between the source and target questionnaires. A well-established guideline resulted in a culturally adapted Brazilian-Portuguese version of the OSDI, tested and validated on a sample of Brazilian population, and proved to be a valid and reliable instrument for assessing patients with dry eye syndrome in Brazil.

Published
2014

37. Impact of mode of delivery on the birth experience in first-time mothers: a qualitative study

Author

Francis Guillemin, Christine Cedraschi, Marie-Julia Guittier, Michel Boulvain, Nasir Jamei, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), University of Applied Sciences of Western Switzerland, Geneva University Hospital (HUG), Faculté de médecine [Genève], Haute École de Santé, Hôpitaux Universitaires de Genève (HUG), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Geneva University Hospital ( HUG ), and Hôpitaux Universitaires de Genève ( HUG )

Subjects
Pediatrics, medicine.medical_treatment, Emotions, [SHS.PSY]Humanities and Social Sciences/Psychology, Developmental psychology, 0302 clinical medicine, MESH: Pregnancy, Pregnancy, Obstetrics and Gynaecology, Childbirth, MESH : Female, Caesarean section, 030212 general & internal medicine, MESH: Qualitative Research, [ SDV.MHEP.GEO ] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Qualitative Research, Vaginal delivery, ddc:618, 030219 obstetrics & reproductive medicine, MESH : Extraction, Obstetrical, Obstetrics and Gynecology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Extraction, Obstetrical, MESH : Adult, MESH: Cesarean Section, MESH: Interviews as Topic, MESH: Mothers, Parity, MESH: Young Adult, MESH : Mothers, MESH : Anesthesia, Spinal, MESH : Anesthesia, Epidural, Female, Thematic analysis, MESH: Anesthesia, Spinal, Research Article, Adult, Anesthesia, Epidural, medicine.medical_specialty, Reproductive medicine, MESH : Young Adult, Mothers, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Anesthesia, Spinal, MESH : Emotions, Interviews as Topic, Delivery experience, 03 medical and health sciences, [ SHS.PSY ] Humanities and Social Sciences/Psychology, Young Adult, MESH : Cesarean Section, medicine, MESH : Qualitative Research, Humans, MESH : Parity, MESH: Emotions, MESH: Humans, business.industry, Cesarean Section, MESH : Humans, MESH: Parity, Parturition, MESH: Adult, medicine.disease, MESH : Pregnancy, MESH : Parturition, MESH : Interviews as Topic, ddc:618.97, Mode of delivery, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Anesthesia, Epidural, Qualitative study, business, MESH: Parturition, MESH: Female, Postpartum period, Qualitative research, MESH: Extraction, Obstetrical
Abstract

International audience; BACKGROUND: The birth of a first child is an important event in a woman's life. Delivery psychological impacts vary depending on whether delivery has been positively or negatively experienced. Delivery experience determinants have been identified but the understanding of their expression according to the mode of delivery is poorly documented. The purpose of the study was to determine important elements associated with women's first delivery experience according to the mode of delivery: vaginal or caesarean section.METHODS: Qualitative approach using thematic content analysis of in-depth interviews conducted between 4 and 6 weeks' postpartum, in 24 primiparous women who delivered at Geneva University Hospital in 2012.RESULTS: Perceived control, emotions, and the first moments with the newborn are important elements for the experience of childbirth. Depending on the mode of delivery these are perceived differently, with a negative connotation in the case of caesarean section. Other elements influencing the delivery experience were identified among all participants, irrespective of the mode of delivery. They included representations, as well as the relationship with caregivers and the father in the delivery room, privacy, unexpected sensory experiences, and ownership of the maternal role. Women's and health professionals' representations sometimes led to a hierarchy based on the mode of delivery and use of analgesia.CONCLUSIONS: The mode of delivery directly impacts on certain key delivery experience determinants as perceived control, emotions, and the first moments with the newborn. The ability/inability of the woman to imagine a second pregnancy is a good indicator of the birth experience. Certain health professional gestures or attitudes can promote a positive delivery experience. We recommend to better prepare women during prenatal classes for the eventuality of a caesarean section delivery and to offer all women and, possibly, their partners, the opportunity to talk about the experience of childbirth during the postpartum period. The results of this study suggest that further research is required on the social representations of women and health professionals regarding the existence of a hierarchy associated with the mode of delivery.

Published
2014

38. Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin

Author

Alexis Elbaz, Janet S. Sinsheimer, Marie-Anne Loriot, Beate Ritz, Daniel D. Buchanan, George D. Mellick, Jerome I. Rotter, Ismaïl Ahmed, Shannon L. Rhodes, Jeff M. Bronstein, Kent D. Taylor, SZTAJNBOK, Pascale, Department of Biology, Indiana University [Bloomington], Indiana University System-Indiana University System-School of Science, Queensland Institute of Medical Research, Laboratoire brestois de mécanique et des systèmes (LBMS), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne), Cedars-Sinai Medical Center, Bases moléculaires de la réponse aux xénobiotiques (U775 (IFR95)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Human Genetics, University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Department of Neurology [UCLA], University of California (UC)-University of California (UC)-David Geffen School of Medicine [Los Angeles], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Eskitis Institute for Cell and Molecular Therapies, Griffith University [Brisbane], Department of Epidemiology, University of California-University of California, University of California-University of California-David Geffen School of Medicine [Los Angeles], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Indiana University [Bloomington]-School of Science, Laboratoire brestois de mécanique et des systèmes ( LBMS ), École Nationale d'Ingénieurs de Brest ( ENIB ) -Université de Brest ( UBO ) -ENSTA Bretagne, Medical Genetics Institute, Cedars-Sinai Medical Center, Bases moléculaires de la réponse aux xénobiotiques ( U775 (IFR95) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), University of California at Los Angeles [Los Angeles] ( UCLA ), University of California at Los Angeles [Los Angeles] ( UCLA ) -David Geffen School of Medicine, Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Griffith University

Subjects
Male, Aging, Parkinson's disease, Epidemiology, MESH : Aged, Neurodegenerative, MESH : Iron, 0302 clinical medicine, Receptors, 2.1 Biological and endogenous factors, MESH : Female, Aetiology, Transferrin receptor 2, MESH: Genetic Association Studies, Genetics, chemistry.chemical_classification, MESH: Aged, 0303 health sciences, MESH: Iron, Parkinson's Disease, MESH: Middle Aged, MESH: Polymorphism, Single Nucleotide, MESH : Polymorphism, Single Nucleotide, Neurodegeneration, Transferrin, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Parkinson Disease, Single Nucleotide, Pooled-analysis, MESH : Adult, Middle Aged, MESH : Transferrin, MESH: Case-Control Studies, 3. Good health, MESH : Parkinson Disease, Neurology, MESH: Young Adult, Neurological, Female, MESH: Transferrin, Adult, MESH : Case-Control Studies, Adolescent, MESH : Male, Iron, Clinical Sciences, MESH : Young Adult, Transferrin receptor, Single-nucleotide polymorphism, Substantia nigra, Biology, Polymorphism, Single Nucleotide, Article, lcsh:RC321-571, 03 medical and health sciences, Young Adult, MESH : Adolescent, Iron homeostasis, Receptors, Transferrin, medicine, Humans, MESH : Middle Aged, MESH : Receptors, Transferrin, MESH: Receptors, Transferrin, Allele, Polymorphism, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Genetic Association Studies, 030304 developmental biology, Aged, MESH: Adolescent, Neurology & Neurosurgery, MESH: Humans, MESH : Humans, Haplotype, Neurosciences, MESH: Adult, MESH : Genetic Association Studies, medicine.disease, MESH: Male, Brain Disorders, chemistry, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Case-Control Studies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Female, 030217 neurology & neurosurgery, MESH: Parkinson Disease
Abstract

Pathologic features of Parkinson's disease (PD) include death of dopaminergic neurons in the substantia nigra, presence of α-synuclein containing Lewy bodies, and iron accumulation in PD-related brain regions. The observed iron accumulation may be contributing to PD etiology but it also may be a byproduct of cell death or cellular dysfunction. To elucidate the possible role of iron accumulation in PD, we investigated genetic variation in 16 genes related to iron homeostasis in three case-control studies from the United States, Australia, and France. After screening 90 haplotype tagging single nucleotide polymorphisms (SNPs) within the genes of interest in the US study population, we investigated the five most promising gene regions in two additional independent case-control studies. For the pooled data set (1289 cases, 1391 controls) we observed a protective association (OR. = 0.83, 95% CI: 0.71-0.96) between PD and a haplotype composed of the A allele at rs1880669 and the T allele at rs1049296 in transferrin (TF; GeneID: 7018). Additionally, we observed a suggestive protective association (OR. = 0.87, 95% CI: 0.74-1.02) between PD and a haplotype composed of the G allele at rs10247962 and the A allele at rs4434553 in transferrin receptor 2 (TFR2; GeneID: 7036). We observed no associations in our pooled sample for haplotypes in SLC40A1, CYB561, or HFE. Taken together with previous findings in model systems, our results suggest that TF or a TF- TFR2 complex may have a role in the etiology of PD, possibly through iron misregulation or mitochondrial dysfunction within dopaminergic neurons. © 2013 Elsevier Inc.

Published
2014

39. Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort

Author

Anne Durnez, Maxime Dougados, Simon Paternotte, Corinne Miceli-Richard, Christian Roux, Karine Briot, Service de rhumatologie [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Groeninge Hospital, Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Physiopathologie des arthrites, Université Louis Pasteur - Strasbourg I, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Cochin [AP-HP], and CHU Strasbourg - Hôpital de Hautepierre [Strasbourg]

Subjects
Male, MESH : Bone Diseases, [SDV]Life Sciences [q-bio], Osteoporosis, Logistic regression, Gastroenterology, MESH: Magnetic Resonance Imaging, Cohort Studies, MESH: Lumbar Vertebrae, MESH : Back Pain, Absorptiometry, Photon, 0302 clinical medicine, MESH : Edema, Bone Density, Risk Factors, MESH: Risk Factors, Edema, Immunology and Allergy, MESH : Female, MESH : Bone Density, Young adult, MESH: Bone Density, MESH: Cohort Studies, MESH : Lumbar Vertebrae, Bone mineral, Sacroiliac joint, 0303 health sciences, Univariate analysis, Lumbar Vertebrae, MESH: Middle Aged, medicine.diagnostic_test, MESH : Spondylarthritis, MESH : Adult, Middle Aged, MESH : Hip Joint, MESH : Risk Factors, Magnetic Resonance Imaging, [SDV] Life Sciences [q-bio], MESH: Edema, C-Reactive Protein, medicine.anatomical_structure, MESH: Young Adult, Erythrocyte sedimentation rate, Female, Hip Joint, France, MESH: Bone Diseases, Bone Diseases, MESH: Osteoporosis, Adult, musculoskeletal diseases, MESH: Hip Joint, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Blood Sedimentation, MESH: Spondylarthritis, Immunology, MESH : Young Adult, MESH : Cohort Studies, Blood Sedimentation, MESH: Absorptiometry, Photon, General Biochemistry, Genetics and Molecular Biology, Young Adult, 03 medical and health sciences, Rheumatology, MESH : Adolescent, MESH : Magnetic Resonance Imaging, Internal medicine, Spondylarthritis, MESH: C-Reactive Protein, medicine, Humans, MESH : Middle Aged, Risk factor, MESH : France, MESH: Blood Sedimentation, MESH : Absorptiometry, Photon, 030304 developmental biology, 030203 arthritis & rheumatology, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH : C-Reactive Protein, medicine.disease, MESH: Male, Surgery, MESH: France, Back Pain, MESH: Back Pain, MESH : Osteoporosis, business, MESH: Female
Abstract

ObjectivesTo assess bone mineral density (BMD) at lumbar spine and hip in a large cohort of patients with early inflammatory back pain (IBP) suggestive of axial spondyloarthritis (SpA), and to assess systemic and bone inflammation (according to MRI) as risk factors of low BMD.Patients and Methods332 (52.4% male) patients with IBP suggestive of axial SpA defined by Calin or Berlin criteria were recruited; they had lumbar spine and hip BMD and body composition measurements. Low BMD was defined by Z≤−2 (at least one site). Clinical, biological (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) and imaging (x-rays, spine and sacroiliac joint MRI) parameters were compared in patients with and without low BMD (Z≤−2). Significant parameters in univariate analysis were tested in multivariate models.ResultsPatients (mean age 33.8 years) had a short duration of axial symptoms (mean 1.6 years); 71.4% fulfilled the Assessment of Spondyloarthritis International Society criteria for axial SpA and HLA-B27 was present in 62.1%. 43 (13.0%) had low BMD (88% male). Multivariate logistic regression showed that parameters significantly associated with low BMD (any site) were the presence of bone marrow oedema (inflammatory lesions) on MRI (OR 4.63, p=0.001), either ESR or CRP (OR 2.60, p=0.037) and male gender (OR 9.60, p=0.0004).ConclusionsThis study conducted in a large cohort of young adults with early IBP suggestive of SpA shows that 13.0% of patients have a low BMD and that the main risk factor associated with low BMD was inflammation on MRI.

Published
2013

40. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study

Author

Raouf Ben Abdelali, Véronique Lhéritier, Jean-Yves Cahn, Françoise Huguet, Norbert Ifrah, Agnès Buzyn, Noémie de Gunzburg, Elizabeth Macintyre, Vahid Asnafi, Dominique Payet-Bornet, Sébastien Maury, Jonathan Bond, Thibaud Leguay, Amélie Trinquand, Bertrand Nadel, André Delannoy, Kheira Beldjord, Hervé Dombret, Xavier Thomas, Jérôme Lambert, Ludovic Lhermitte, Hossein Mossafa, Etienne Lengliné, Yves Chalandon, Caroline Bonmati, Aline Tanguy-Schmidt, Centre d'Immunologie de Marseille - Luminy ( CIML ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Cytogénétique - Pasteur-Cerba, Laboratoire Pasteur-Cerba, Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ), Hôpital de Jolimont, Haine-Saint-Paul and Cliniques Universitaires St Luc, Service hématologie, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Service d'hématologie clinique [Avicenne], Université Paris 13 ( UP13 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, Lymphocyte et cancer, IFR105-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], IFR105-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Université Toulouse III - Paul Sabatier (UT3), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre de Recherche en Cancérologie de Lyon (CRCL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Ras Proteins/genetics, Oncology, Pathology, MESH : F-Box Proteins, DNA Mutational Analysis, Cell Cycle Proteins, MESH : Gene Deletion, MESH: Receptor, Notch1, 0302 clinical medicine, MESH : Cell Cycle Proteins, Receptor, Notch1, MESH: DNA Mutational Analysis, Young adult, ddc:616, 0303 health sciences, Hazard ratio, PTEN Phosphohydrolase/genetics, hemic and immune systems, 3. Good health, MESH : Phenotype, MESH: Young Adult, 030220 oncology & carcinogenesis, Predictive value of tests, Cohort, F-Box Proteins/genetics, MESH : Proto-Oncogene Proteins, MESH: Membrane Proteins, MESH: ras Proteins, medicine.medical_specialty, MESH : Young Adult, MESH : DNA Mutational Analysis, MESH: Phenotype, MESH: PTEN Phosphohydrolase, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, MESH: Cell Cycle Proteins, Humans, PTEN, Ubiquitin-Protein Ligases/genetics, MESH : Predictive Value of Tests, MESH: Kaplan-Meier Estimate, Cell Cycle Proteins/genetics, Receptor, Notch1/genetics, [ SDV.IMM.II ] Life Sciences [q-bio]/Immunology/Innate immunity, MESH: Humans, Proportional hazards model, F-Box Proteins, MESH : Humans, MESH: Adult, MESH : Proportional Hazards Models, MESH: Ubiquitin-Protein Ligases, MESH : Membrane Proteins, MESH: Disease-Free Survival, Mutation, ras Proteins, Adult Acute Lymphoblastic Leukemia, MESH : Genetic Predisposition to Disease, MESH : Ubiquitin-Protein Ligases, MESH : GTP Phosphohydrolases, MESH: Female, Gene Deletion, Cancer Research, F-Box-WD Repeat-Containing Protein 7, Time Factors, MESH : Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Kaplan-Meier Estimate, MESH : PTEN Phosphohydrolase, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, GTP Phosphohydrolases, MESH: Proportional Hazards Models, MESH: Risk Factors, Risk Factors, hemic and lymphatic diseases, MESH : Female, biology, MESH : Receptor, Notch1, MESH: Genetic Predisposition to Disease, MESH : Adult, MESH : Risk Factors, MESH: Predictive Value of Tests, MESH: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Phenotype, MESH : Disease-Free Survival, Female, MESH : Mutation, MESH : Time Factors, Adult, MESH: Mutation, MESH: GTP Phosphohydrolases, Ubiquitin-Protein Ligases, MESH : Male, MESH: F-Box Proteins, MESH: Multivariate Analysis, MESH : Kaplan-Meier Estimate, Young Adult, Predictive Value of Tests, Proto-Oncogene Proteins, Internal medicine, medicine, Genetic Predisposition to Disease, Membrane Proteins/genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/classification/genetics/mortality/therapy, Proportional Hazards Models, 030304 developmental biology, business.industry, MESH: Time Factors, PTEN Phosphohydrolase, Membrane Proteins, MESH : Multivariate Analysis, GTP Phosphohydrolases/genetics, MESH: Male, MESH: Proto-Oncogene Proteins, Proto-Oncogene Proteins/genetics, MESH: Gene Deletion, Multivariate Analysis, biology.protein, MESH : ras Proteins, business
Abstract

Purpose The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome in T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL. Despite this, one third of patients with N/F-mutated T-ALL experienced relapse. Patients and Methods In a series of 212 adult T-ALLs included in the multicenter randomized GRAALL-2003 and -2005 trials, we searched for additional N/K-RAS mutations and PTEN defects (mutations and gene deletion). Results N/F mutations were identified in 143 (67%) of 212 patients, and lack of N/F mutation was confirmed to be associated with a poor prognosis. K-RAS, N-RAS, and PTEN mutations/deletions were identified in three (1.6%) of 191, 17 (8.9%) of 191, and 21 (12%) of 175 patients, respectively. The favorable prognostic significance of N/F mutations was restricted to patients without RAS/PTEN abnormalities. These observations led us to propose a new T-ALL oncogenetic classifier defining low-risk patients as those with N/F mutation but no RAS/PTEN mutation (97 of 189 patients; 51%) and all other patients (49%; including 13% with N/F and RAS/PTEN mutations) as high-risk patients. In multivariable analysis, this oncogenetic classifier remained the only significant prognostic covariate (event-free survival: hazard ratio [HR], 3.2; 95% CI, 1.9 to 5.15; P < .001; and overall survival: HR, 3.2; 95% CI, 1.9 to 5.6; P < .001). Conclusion These data demonstrate that the presence of N/F mutations in the absence of RAS or PTEN abnormalities predicts good outcome in almost 50% of adult T-ALL. Conversely, the absence of N/F or presence of RAS/PTEN alterations identifies the remaining cohort of patients with poor prognosis.

Published
2013

41. Candida albicans is not always the preferential yeast colonizing humans: a study in Wayampi Amerindians

Author

Mouna Ben Soltana, Laure Diancourt, Antoine Andremont, Paul-Louis Woerther, Sophie Abélanet, Félix Djossou, Emmanuelle Permal, Cécile Angebault, Christiane Bouchier, Christophe d'Enfert, François Catzeflis, Marie-Elisabeth Bougnoux, CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Laboratoire de bactériologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Biologie et Pathogénicité fongiques, Institut National de la Recherche Agronomique (INRA)-Institut Pasteur [Paris], Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyanne Française], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Génotypage des Pathogènes et Santé Publique (Plate-forme) (PF8), Institut Pasteur [Paris], Génomique (Plate-Forme), Institut des Sciences de l'Evolution de Montpellier (UMR ISEM), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École pratique des hautes études (EPHE)-Université de Montpellier (UM)-Institut de recherche pour le développement [IRD] : UR226-Centre National de la Recherche Scientifique (CNRS), The ERAES project was supported in part by the Agence Française de Sécurité Sanitaire de l’Environnement et du Travail(contracts ES-05-01 and EST-09-21), the Agence Nationale pour la Recherche (contract 05-9-114), the Institut National de la Santé et de la Recherche Médicale (INSERM, contracts C06-18 and C10-19), the Centre National de Référence' Résistance bactérienne dans les flores commensales, 'the Fondation pour la Recherche Médicale (grants FDM20090615761 andFDM20100619023 to C. A.), and the French government ’ s Investissement d'Avenir program, Laboratoire d’Excellence'Integrative Biology of Emerging Infectious Diseases' (grant ANR-10-LABX-62-IBEID), ANR: the Agence Nationale pour la Recher- che (contract 05-9-114),the Agence Nationale pour la Recher- che (contract 05-9-114),05-9-114 the Agence Nationale pour la Recher- che (contract 05-9-114), ANR-10-LABX-62-IBEID,IBEID,Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases'(2010), Assistance publique - Hôpitaux de Paris (AP-HP) - AP-HP - Hôpital Bichat - Claude Bernard [Paris] - Université Paris Diderot - Paris 7 (UPD7), Institut National de la Recherche Agronomique (INRA) - Institut Pasteur [Paris], Institut des Sciences de l'Evolution de Montpellier (ISEM), Université de Montpellier (UM) - Institut de recherche pour le développement [IRD] : UR226 - Centre National de la Recherche Scientifique (CNRS), ANR : the Agence Nationale pour la Recher- che (contract 05-9-114), the Agence Nationale pour la Recher- che (contract 05-9-114), 05-9-114 the Agence Nationale pour la Recher- che (contract 05-9-114), ANR-10-LABX-62-IBEID, IBEID, Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases'(2010), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur [Paris]-Institut National de la Recherche Agronomique (INRA), Génomique (Plate-Forme) - Genomics Platform, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Montpellier (UM)-Institut de recherche pour le développement [IRD] : UR226-Centre National de la Recherche Scientifique (CNRS), 05-9-114 the Agence Nationale pour la Recher- che (contract 05-9-114) the Agence Nationale pour la Recher- che (contract 05-9-114), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), Biologie et Pathogénicité fongiques (BPF), Institut National de la Recherche Agronomique (INRA)-Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP), and Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École Pratique des Hautes Études (EPHE)

Subjects
Male, MESH : Prevalence, MESH : Multilocus Sequence Typing, MESH : Aged, MESH : Candidiasis, MESH: Aged, 80 and over, Prevalence, Immunology and Allergy, Colonization, MESH : Female, MESH: Animals, Candida albicans, MESH: Phylogeny, Phylogeny, MESH: Evolution, Molecular, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Aged, 80 and over, 2. Zero hunger, MESH : Intestines, MESH: Aged, 0303 health sciences, MESH: Middle Aged, biology, MESH: Yeasts, Candidiasis, intestinal colonization, Middle Aged, MESH : Adult, Corpus albicans, MESH: Candidiasis, French Guiana, Intestines, Infectious Diseases, MESH : Carrier State, MESH: Multilocus Sequence Typing, whole-genome sequencing, MESH: Young Adult, Carrier State, MESH: Genome, Fungal, Female, Genome, Fungal, MESH: Carrier State, MLST, MESH: Intestines, Adult, MESH : French Guiana, Adolescent, Human intestine, MESH : Candida albicans, MESH : Male, Saccharomyces cerevisiae, MESH : Young Adult, yeasts, Microbiology, Evolution, Molecular, Young Adult, 03 medical and health sciences, MESH: Mycoses, Candida krusei, MESH : Adolescent, MESH: French Guiana, Animals, Humans, MESH : Middle Aged, MESH : Evolution, Molecular, MESH : Aged, 80 and over, MESH: Prevalence, Aged, 030304 developmental biology, MESH : Mycoses, MESH: Adolescent, MESH : Yeasts, MESH: Humans, 030306 microbiology, amerindians, MESH : Genome, Fungal, MESH: Candida albicans, MESH : Humans, MESH : Phylogeny, MESH: Adult, biology.organism_classification, [SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Yeast, MESH: Male, Carriage, Mycoses, candida albicans, MESH : Animals, MESH: Female, Multilocus Sequence Typing
Abstract

Chantier qualité GA; International audience; In industrialized countries Candida albicans is considered the predominant commensal yeast of the human intestine, with approximately 40% prevalence in healthy adults. We discovered a highly original colonization pattern that challenges this current perception by studying in a 4- year interval a cohort of 151 Amerindians living in a remote community (French Guiana), and animals from their environment. The prevalence of C. albicans was persistently low (3% and 7% of yeast carriers). By contrast, Candida krusei and Saccharomyces cerevisiae were detected in over 30% of carriers. We showed that C. krusei and S. cerevisiae carriage was of food or environmental origin, whereas C. albicans carriage was associated with specific risk factors (being female and living in a crowded household). We also showed using whole-genome sequence comparison that C. albicans strains can persist in the intestinal tract of a healthy individual over a 4-year period.

Published
2013

42. [Medical indoor environment counsellor (MIEC) in Burgundy: evaluation by physicians and patients]

Author

Vagner , A, Reboux , G, Nicoullaud , V, Blanchon , L, Scherer , P, Collet , E, Camus , P, Foglia , T, Gardin , G, Bonniaud , P, Service de Pneumologie et unité de soins intensifs respiratoire, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ), Retinoids, Development and Developmental Diseases ( R2D2 ), Université d'Auvergne - Clermont-Ferrand I ( UdA ), Departments of Cell Biology and Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service des maladies respiratoires [CHU de Dijon], Millon, Laurence, Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Retinoids, Development and Developmental Diseases (R2D2), Université d'Auvergne - Clermont-Ferrand I (UdA), Albert Einstein College of Medicine [New York], and Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE)

Subjects
Counseling, Male, MESH: Asthma, MESH : Aged, MESH : Child, Preschool, MESH: Aged, 80 and over, MESH : Child, MESH: Child, MESH: Physicians, MESH: Animals, MESH : Female, Child, Rhinitis, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, MESH : Rhinitis, MESH: Counseling, MESH: Rhinitis, Pyroglyphidae, MESH: Patient Acceptance of Health Care, MESH : Infant, Middle Aged, MESH : Adult, MESH: Infant, MESH : Patient Acceptance of Health Care, MESH : Counseling, MESH : Air Pollution, Indoor, MESH: Young Adult, Patient Satisfaction, Air Pollution, Indoor, Child, Preschool, Female, France, MESH : Skin Tests, Adult, MESH : Patient Satisfaction, Adolescent, MESH : Male, MESH : Physicians, MESH : Young Adult, MESH : Asthma, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, Young Adult, MESH: Skin Tests, Physicians, MESH : Adolescent, [SDV.EE.SANT] Life Sciences [q-bio]/Ecology, environment/Health, Animals, Humans, MESH : Middle Aged, MESH : Pyroglyphidae, MESH: Pyroglyphidae, MESH : France, MESH : Aged, 80 and over, Aged, Skin Tests, MESH: Adolescent, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, MESH: Humans, MESH: Child, Preschool, MESH : Humans, Infant, MESH: Adult, Patient Acceptance of Health Care, MESH: Male, MESH: Patient Satisfaction, Asthma, respiratory tract diseases, MESH: France, MESH : Animals, MESH: Air Pollution, Indoor, MESH: Female
Abstract

International audience; Since December 2009, chest physicians and allergologists in Burgundy have been able to call upon a medical indoor environment counsellor (MIEC). The consultations are free for the patient and are undertaken following a medical referal after systematic cutaneous prick tests. To describe the indications, the distribution of prescriptions and to measure the impact of the counsellor's visits on the first 100 patients at 6 months and on the physicians at 18 months. Telephone interviews with the 67 physicians (whether prescribers or not) concerning their motivation and/or expectations, and with the first 100 patients concerning follow up of the recommendations. Seventy percent of the physicians replied (n=47). The satisfaction of prescribers (n=22) was 8.42/10. The indications were rhinitis and a poorly controlled asthma. The requests concerned the search for dust mite (50%) and moulds (46%). Eighty-four percent of the physicians discussed the MIEC's report with the patients. The patients' symptoms were rhinitis (79%), asthma (57%) and conjunctivitis (33%). The Acarex test(®), performed in cases of positive prick tests to house dust mites (n=72), was strongly positive for 67 patients. Sixteen mould samples out of 21 were above the standard concentrations. Sixty-nine patients had followed the recommendations of the MIEC. The impact of the MIEC visits was perceived as positive by the physicians and the patients. The medico-economic impact warrants further evaluation.

Published
2013

43. Acute lower respiratory infections on lung sequelae in Cambodia, a neglected disease in highly tuberculosis-endemic country

Author

Arnaud Tarantola, Patrich Lorn Try, Sophie Goyet, Sopheak Hem, Blandine Rammaert, Bertrand Guillard, Sokleaph Cheng, Charles Mayaud, Sirenda Vong, Laurence Borand, Sareth Rith, Philippe Buchy, Vantha Te, Institut Pasteur du Cambodge, Institut Pasteur du Cambodge-Réseau International des Instituts Pasteur ( RIIP ), Centre d'infectiologie Necker-Pasteur, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Donkeo Provincial Hospital, CHU Tenon [APHP], Rammaert B, Goyet S, Mayaud C, Buchy P, Borand L., Tarantola A, Hem S, Rith S, Cheng S, Te V, Try PL, Guillard B, Vong S, CHU Necker - Enfants Malades [AP-HP], Kampong Cham Provincial hospital, Kampong Cham Provincial hospital [Cambodia], Surveillance and Investigation of endemic situations in South-East Asia (SISEA) was funded by the French Agency for Development (Agence Française de Développement, AFD) and the US Department of Human and Health Services (US DHHS). Blandine Rammaert received a grant from the Fondation Pierre Ledoux Jeunesse Internationale and the Société de Pathologie Infectieuse de Langue Française., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Réseau International des Instituts Pasteur (RIIP), CHU Tenon [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, MESH : Prospective Studies, MESH : Aged, Haemophilus influenzae, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Prospective Studies, MESH: Developing Countries, Respiratory Tract Infections, Aged, 80 and over, MESH: Middle Aged, MESH : Acute Disease, Neglected Diseases, MESH : Superinfection, MESH : Diagnosis, Differential, Countries, 3. Good health, Bronchiectasis, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Young Adult, Acute Disease, MESH: Acute Disease, MESH : Hospitalization, MESH : Endemic Diseases, MESH : Community-Acquired Infections, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, MESH : Young Adult, [ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Article, 03 medical and health sciences, MESH: Anti-Bacterial Agents, MESH : Adolescent, Humans, MESH : Middle Aged, MESH : Developing Countries, Intensive care medicine, MESH : Aged, 80 and over, MESH: Age Distribution, Developing Countries, Tuberculosis, Pulmonary, Aged, MESH: Adolescent, MESH: Tuberculosis, Pulmonary, MESH: Humans, MESH : Cambodia, MESH : Humans, MESH: Adult, medicine.disease, 030228 respiratory system, Superinfection, Developing, Chest radiograph, MESH: Female, MESH : Tuberculosis, Pulmonary, Endemic Diseases, MESH : Age Distribution, MESH : Respiratory Tract Infections, MESH: Hospitalization, medicine.disease_cause, MESH: Aged, 80 and over, MESH : Female, 030212 general & internal medicine, Respiratory system, MESH : Anti-Bacterial Agents, MESH: Aged, medicine.diagnostic_test, Airway remodeling, MESH : Adult, Middle Aged, Anti-Bacterial Agents, Community-Acquired Infections, Hospitalization, medicine.anatomical_structure, MESH: Community-Acquired Infections, MESH: Endemic Diseases, Pseudomonas aeruginosa, Female, Abnormality, Cambodia, Adult, Adolescent, MESH : Male, Diagnosis, Differential, Young Adult, Age Distribution, MESH: Diagnosis, Differential, Internal medicine, Streptococcus pneumoniae, medicine, Lung, business.industry, MESH: Cambodia, MESH: Male, MESH: Prospective Studies, MESH: Superinfection, MESH: Respiratory Tract Infections, MESH: Neglected Diseases, business, MESH : Neglected Diseases
Abstract

International audience; BACKGROUND: Little is known about post-infectious pulmonary sequelae in countries like Cambodia where tuberculosis is hyper-endemic and childhood pulmonary infections are highly frequent. We describe the characteristics of hospitalized Cambodian patients presenting with community-acquired acute lower respiratory infections (ALRI) on post-infectious pulmonary sequelae (ALRIPS). METHODS: Between 2007 and 2010, inpatients ≥15 years with ALRI were prospectively recruited. Clinical, biological, radiological and microbiological data were collected. Chest radiographs were re-interpreted by experts to compare patients with ALRIPS, on previously healthy lungs (ALRIHL) and active pulmonary tuberculosis (TB). Patients without chest radiograph abnormality or with abnormality suggestive as other chronic respiratory diseases were excluded from this analysis. RESULTS: Among the 2351 inpatients with community-acquired ALRI, 1800 were eligible: 426 (18%) ALRIPS, 878 (37%) ALRIHL and 496 (21%) TB. ALRIPS patients had less frequent fever than other ALRI (p

Published
2013

44. Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DESIR cohort

Author

Floris A. van Gaalen, Bernard Combe, Victoria Navarro-Compán, Désirée van der Heijde, Claudine Cosson, Department of Rheumatology (LEIDEN - Rhumato), Leiden University Medical Center (LUMC), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service de Biochimie [Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Department of Rheumatology ( LEIDEN - Rhumato ), Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - IURC, Université Montpellier 1 ( UM1 ) -Université de Montpellier ( UM ), Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), and Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre

Subjects
Male, [SDV]Life Sciences [q-bio], Cohort Studies, 0302 clinical medicine, Immunology and Allergy, MESH : Female, 030212 general & internal medicine, Axial spondyloarthritis, MESH: Cohort Studies, ComputingMilieux_MISCELLANEOUS, medicine.diagnostic_test, biology, Desir cohort, MESH : Spondylarthritis, MESH : Adult, 3. Good health, C-Reactive Protein, MESH: Young Adult, Female, MESH : Sensitivity and Specificity, Adult, medicine.medical_specialty, MESH : Male, MESH: Spondylarthritis, Immunology, MESH : Young Adult, MESH : Cohort Studies, Sensitivity and Specificity, General Biochemistry, Genetics and Molecular Biology, Disease activity, 03 medical and health sciences, Young Adult, Rheumatology, Internal medicine, MESH: C-Reactive Protein, Spondylarthritis, medicine, Humans, In patient, Symptom onset, 030203 arthritis & rheumatology, MESH: Humans, [ SDV ] Life Sciences [q-bio], business.industry, C-reactive protein, MESH : Humans, MESH: Biological Markers, Magnetic resonance imaging, MESH: Adult, Baseline data, MESH : C-Reactive Protein, MESH: Male, MESH: Sensitivity and Specificity, MESH : Biological Markers, biology.protein, Physical therapy, business, MESH: Female, Biomarkers
Abstract

The average delay in axial spondyloarthritis (axSpA) diagnosis after symptom onset is one of the longest among inflammatory rheumatic diseases.1 New tools, such as magnetic resonance imaging,2 have been developed to reduce this delay. Elevated C-reactive protein (CRP) has been incorporated as one of the features for Assessment of SpondyloArthritis international Society (ASAS) SpA criteria,3 and in the Berlin diagnostic algorithm.4 However, CRP levels are elevated in only a minority of early SpA patients.5 More sensitive tests, so-called high-sensitivity CRP (hsCRP), have been developed and can detect lower concentrations of CRP compared with traditional methods.6 HsCRP levels are increased in other rheumatic chronic inflammatory diseases,7 and show a better correlation with disease activity parameters compared with routine CRP in patients with axSpA.8 Therefore, hsCRP could be more sensitive than traditional CRP in diagnosing axial SpA. The aim of this study was to assess the contribution of hsCRP versus CRP to classification of early axSpA using the ASAS criteria. Baseline data …

Published
2013

45. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy

Author

Olivier Humbert, Alexandre Cochet, Salim Kanoun, Caroline Legouge, François Brunotte, Olivier Casasnovas, Inna Dygai-Cochet, Alina Berriolo-Riedinger, Michel Toubeau, Louis Berthet, Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Nucléaire, UNICANCER-UNICANCER, Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )

Subjects
MESH : Bone Marrow, Male, MESH : Retrospective Studies, Biopsy, MESH : Aged, Iliac crest, MESH : Lymphoma, Large B-Cell, Diffuse, Multimodal Imaging, 030218 nuclear medicine & medical imaging, [ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Biopsy, 0302 clinical medicine, International Prognostic Index, MESH: Aged, 80 and over, MESH: Fluorodeoxyglucose F18, Bone Marrow, MESH : Tomography, X-Ray Computed, MESH : Neoplasm Staging, MESH : Female, MESH: Aged, Aged, 80 and over, MESH : Prognosis, MESH: Middle Aged, medicine.diagnostic_test, MESH: Multimodal Imaging, MESH: Neoplasm Staging, MESH : Adult, Middle Aged, Prognosis, MESH: Positron-Emission Tomography, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH: Bone Marrow, Female, Radiology, Lymphoma, Large B-Cell, Diffuse, MESH: Tomography, X-Ray Computed, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Multimodal Imaging, MESH : Young Adult, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Prognosis, 03 medical and health sciences, Young Adult, Fluorodeoxyglucose F18, MESH : Adolescent, medicine, Humans, Radiology, Nuclear Medicine and imaging, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, Neoplasm Staging, Retrospective Studies, MESH: Adolescent, PET-CT, MESH: Humans, business.industry, MESH : Humans, MESH : Positron-Emission Tomography, MESH: Adult, MESH: Retrospective Studies, MESH : Fluorodeoxyglucose F18, medicine.disease, Survival Analysis, MESH: Male, Lymphoma, Concomitant, MESH : Biopsy, Positron-Emission Tomography, MESH: Lymphoma, Large B-Cell, Diffuse, Bone marrow, MESH : Survival Analysis, business, Nuclear medicine, Tomography, X-Ray Computed, Diffuse large B-cell lymphoma, MESH: Female
Abstract

International audience; UNLABELLED: In newly diagnosed diffuse large B-cell lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow involvement (BMI) can be low because of sampling error if the BMI is focal and not diffuse. Although (18)F-FDG PET/CT is now recommended for initial staging of DLBCL, its role regarding BMI is not well defined. This study evaluated whether (18)F-FDG PET/CT, in comparison with BMB, is useful for the detection of BMI and predictive of outcome. METHODS: From the 142 patients who were referred to our institution for newly diagnosed DLBCL from June 2006 to October 2011, 133 were retrospectively enrolled in our study. All patients underwent whole-body (18)F-FDG PET/CT and a BMB from the iliac crest before any treatment. (18)F-FDG PET/CT was considered positive for BMI in cases of uni- or multifocal bone marrow (18)F-FDG uptake that could not be explained by benign findings on the underlying CT image or history. A final diagnosis of BMI was considered if the BMB was positive or if the positive (18)F-FDG PET/CT was confirmed by guided biopsy or targeted MR imaging or in cases of disappearance of focal bone marrow uptake concomitant with the disappearance of uptake in other lymphoma lesions on (18)F-FDG PET/CT monitoring. Progression-free survival and overall survival were analyzed using the Cox proportional hazards regression model. RESULTS: Thirty-three patients were considered to have BMI. Of these, 8 were positive according to the BMB and 32 were positive according to (18)F-FDG PET/CT. (18)F-FDG PET/CT was more sensitive (94% vs. 24%; P < 0.001), showed a higher negative predictive value (98% vs. 80%), and was more accurate (98% vs. 81%) than BMB. Median follow-up was 24 mo (range, 1-67 mo). Twenty-nine patients (22%) experienced recurrence or disease progression during follow-up, and 20 patients died (15%). In multivariate analysis, only the International Prognostic Index and the (18)F-FDG PET/CT bone marrow status were independent predictors of progression-free survival (P = 0.005 and 0.02, respectively), whereas only the International Prognostic Index remained an independent predictor of overall survival (P = 0.004). CONCLUSION: Assessment of BMI with (18)F-FDG PET/CT provides better diagnostic performance and prognostic stratification in newly diagnosed DLBCL than does BMB.

Published
2013

46. Associated factors with adherence to antiepileptic drug in the capital city of Lao PDR

Author

Freddy Perez, Hubert Barennes, Pierre-Marie Preux, Sebastien Clavel, Phetvongsinh Chivorakul, Aina Harimanana, Neuroépidémiologie Tropicale ( NET ), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] ( SIME ), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges ( UNILIM ), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), and Université de Limoges (UNILIM)

Subjects
Male, Pediatrics, Urban Population, Cross-sectional study, Psychological intervention, Logistic regression, law.invention, Epilepsy, 0302 clinical medicine, MESH : Cross-Sectional Studies, Randomized controlled trial, law, Medicine, MESH : Female, 030212 general & internal medicine, Functional illiteracy, MESH : Epilepsy, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, 3. Good health, MESH: Urban Population, Neurology, MESH: Young Adult, Laos, MESH: Epilepsy, MESH : Urban Population, Anticonvulsants, Female, Adult, MESH : Anticonvulsants, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Young Adult, Medication Adherence, Young Adult, 03 medical and health sciences, MESH: Anticonvulsants, MESH: Cross-Sectional Studies, MESH : Adolescent, MESH : Medication Adherence, Humans, Medical prescription, MESH: Adolescent, MESH: Humans, business.industry, Public health, MESH : Humans, MESH: Adult, MESH: Medication Adherence, medicine.disease, MESH: Male, Cross-Sectional Studies, MESH: Laos, Family medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), business, MESH: Female, 030217 neurology & neurosurgery, MESH : Laos
Abstract

International audience; Available medical care for epilepsy and antiepileptic drugs (AED) are provided in Vientiane Municipality by district hospitals supported by a non-governmental organization, which is referred to as a community-based intervention (CB), and reference hospital which is referred to as hospital-based interventions (HB). Identifying underlying factors of AED adherence is of public health interest. A community-based cross-sectional survey among randomly selected patients with epilepsy (PWE) who were being cared in Vientiane Municipality was undertaken in 2010. The Morisky scale was used to assess the level of adherence. Univariate and multivariate logistic regression analyses were performed to address predictive factors. Overall, 99 PWE were included in the study. Overall adherence was estimated at 57.6%, 57.1% and 58.0% for the HB and CB group, respectively. High level of adherence was related to illiteracy, being on monotherapy and experiencing fewer seizures. Implementing closer medical care at primary level to PWE improves the likelihood of reducing primary and secondary treatment gap which is related to PWEs' adherence. An active intervention through a downstream channel of training of medical health staff from reference level to community level enhances the prescription of adequate AED, the improvement of the quality of relation between PWE and medical staff.

Published
2013

47. Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study

Author

Brigitte Colombies, Claude Conri, Philippe Lacroix, Anne-Marie Deletraz, V. Guérin, Joël Constans, Joseph Emmerich, Alessandra Bura-Rivière, Gabriel Camelot, Jean-Pierre Cambou, Rémi Le Trequesser, Geneviève Freyburger, Samir Mesli, Virginie Vanbrugghe, Aurélie Bedel, Alan T. Nurden, Luc Bressolette, Annie M. Bérard, Michel Darmon, François Becker, Marie-Christine Vergnes, Sylvie Colomer, Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Hématologie, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Gironde, Laboratoire d'hémostase, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux], Hager Group, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Risque Thrombotique et Mecanismes de l'Hemostase (U765), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement (IFR71), Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Biology, CHU Bordeaux [Bordeaux], Imagerie Fonctionnelle et Métabolique en Oncologie, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Départment de Neuroradiologie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département de Médecine Interne et Pneumologie [Brest] ( DMIP - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Neuroépidémiologie Tropicale ( NET ), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ) -CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Risque Thrombotique et Mecanismes de l'Hemostase ( U765 ), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement ( IFR71 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Unité de Neuroradiologie, CHU Caen, Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

Subjects
Male, Pathology, Apolipoprotein B, MESH : Polymorphism, Genetic, Epidemiology, lcsh:Medicine, 030204 cardiovascular system & hematology, Cardiovascular, Biochemistry, Gastroenterology, MESH : Thromboangiitis Obliterans, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH: Peripheral Arterial Disease, Medicine, MESH : Female, Platelet, 030212 general & internal medicine, Young adult, Family history, lcsh:Science, Peripheral Vascular Diseases, Multidisciplinary, MESH: Middle Aged, biology, Smoking, Age Factors, Thromboangiitis Obliterans, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Genomics, MESH : Adult, Middle Aged, MESH : Risk Factors, Lipids, MESH: Case-Control Studies, 3. Good health, Peripheral, MESH : Smoking, MESH : Histocompatibility Antigens Class II, MESH: Young Adult, Blood Chemistry, Female, Research Article, Adult, MESH: Thromboangiitis Obliterans, MESH : Case-Control Studies, medicine.medical_specialty, MESH: Smoking, Adolescent, Clinical Research Design, MESH : Male, MESH : Young Adult, Peripheral Arterial Disease, Young Adult, 03 medical and health sciences, Genomic Medicine, Diagnostic Medicine, MESH : Adolescent, Internal medicine, MESH: Polymorphism, Genetic, Factor V Leiden, Humans, MESH : Middle Aged, Genetic Testing, Biology, MESH: Adolescent, MESH: Age Factors, Polymorphism, Genetic, MESH: Humans, Population Biology, business.industry, lcsh:R, MESH : Humans, Histocompatibility Antigens Class II, Case-control study, MESH: Adult, MESH : Peripheral Arterial Disease, medicine.disease, MESH: Male, Case-Control Studies, biology.protein, MESH: Histocompatibility Antigens Class II, lcsh:Q, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Age Factors, business, MESH: Female, Lipoprotein
Abstract

International audience; BACKGROUND: This study aimed to determine the prevalence of genetic and environmental vascular risk factors in non diabetic patients with premature peripheral arterial disease, either peripheral arterial occlusive disease or thromboangiitis obliterans, the two main entities of peripheral arterial disease, and to established whether some of them are specifically associated with one or another of the premature peripheral arterial disease subgroups. METHODS AND RESULTS: This study included 113 non diabetic patients with premature peripheral arterial disease (diagnosis

Published
2013

48. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study

Author

Eric Delabesse, Xavier Thomas, Véronique Lhéritier, Nicolas Pottier, Jean-Yves Cahn, Elizabeth Macintyre, Soizic Guihard, Nathalie Grardel, Meyling Cheok, Arnaud Pigneux, Céline Berthon, Hervé Dombret, Norbert Ifrah, Pauline Peyrouze, Marie C. Béné, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Impact de l'environnement chimique sur la santé humaine - ULR 4483 (IMPECS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Service d'Immunologie [CHRU Nancy], Service hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Lymphocyte et cancer, IFR105-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie clinique [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de recherche Jean-Pierre Aubert-Neurosciences et Cancer, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lille, Droit et Santé, Impact de l'Environnement Chimique sur la Santé Humain, PRES Université Lille Nord de France, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), IFR105-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne-Université Paris 13 ( UP13 ), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc - U837 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université Lille 2 - Faculté de Médecine, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne

Subjects
Male, MESH : Transcription Factors, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: CCAAT-Enhancer-Binding Proteins, 0302 clinical medicine, CDKN2A, MESH : Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH : Female, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, MESH: Middle Aged, MESH: Polymorphism, Single Nucleotide, MESH : Polymorphism, Single Nucleotide, MESH: Genetic Predisposition to Disease, Hematology, MESH: Transcription Factors, MESH: Ikaros Transcription Factor, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH : Adult, 3. Good health, DNA-Binding Proteins, MESH : CCAAT-Enhancer-Binding Proteins, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, MESH : DNA-Binding Proteins, Adult, MESH : Male, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Polymorphism, Single Nucleotide, 03 medical and health sciences, Ikaros Transcription Factor, Young Adult, MESH : Ikaros Transcription Factor, Humans, Genetic Predisposition to Disease, MESH : Middle Aged, 030304 developmental biology, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH: Humans, MESH : Humans, MESH: Adult, CEBPE, MESH: Male, Immunology, CCAAT-Enhancer-Binding Proteins, Lymphoblastic leukaemia, MESH : Genetic Predisposition to Disease, MESH: Female, MESH: DNA-Binding Proteins, Transcription Factors
Abstract

International audience

Published
2012

49. Responsiveness of the motor function measure in neuromuscular diseases

Author

Vuillerot, Carole, Payan, Christine, Girardot, Françoise, Fermanian, Jacques, Iwaz, Jean, Bérard, Carole, Ecochard, René, Salle, Jean-Yves, Study Group, Mfm, Renseigné, Non, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de Biostatistiques [Lyon], Hospices Civils de Lyon (HCL), Service de Médecine Physique et de Réadaptation [CHU Limoges], CHU Limoges, Handicap, Activité, Vieillissement, Autonomie, Environnement (HAVAE), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pharmacologie Clinique, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Laboratoire Biostatistique-Santé ( LBS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Handicap, Activité, Vieillissement, Autonomie, Environnement ( HAVAE ), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), and Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM )

Subjects
Male, MESH: Neuromuscular Diseases, medicine.medical_treatment, Psychological intervention, MESH : Prospective Studies, MESH : Aged, Poison control, MESH: Perception, Disability Evaluation, 0302 clinical medicine, MESH : Child, MESH: Child, MESH : Neuromuscular Diseases, Medicine, MESH : Female, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Child, MESH: Physical Therapy Modalities, MESH: Aged, Rehabilitation, MESH: Middle Aged, MESH: Disability Evaluation, Neuromuscular Diseases, Middle Aged, MESH : Adult, MESH : Mobility Limitation, 3. Good health, Motor Skills, MESH: Young Adult, MESH : Motor Skills, Female, Adult, medicine.medical_specialty, Neuromuscular disease, Adolescent, MESH : Male, MESH : Young Adult, Physical Therapy, Sports Therapy and Rehabilitation, MESH : Disability Evaluation, 03 medical and health sciences, Young Adult, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Injury prevention, MESH: Mobility Limitation, MESH: Muscular Dystrophy, Duchenne, Humans, MESH : Middle Aged, Mobility Limitation, MESH : Perception, Physical Therapy Modalities, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Clinical trial, Muscular Dystrophy, Duchenne, MESH : Physical Therapy Modalities, Physical therapy, Observational study, Perception, sense organs, business, MESH : Muscular Dystrophy, Duchenne, MESH: Female, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, MESH: Motor Skills
Abstract

International audience; OBJECTIVES: To study the responsiveness (sensitivity to change) of the Motor Function Measure (MFM) in detecting change in neuromuscular disease patients with the intent of using this measure in future clinical trials. DESIGN: Prospective cohort observational study. SETTING: Inpatient and outpatient facilities for follow-up and treatment of neuromuscular diseases. PARTICIPANTS: Patients (N=152) with various neuromuscular diseases aged 6 to 60 years. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE(S): We used the MFM total score and its 3 subscores on 2 measurements grossly 1 year apart. The physicians and the patients (or proxy) were asked to provide their perceived change in functional status since the first MFM. These changes were expressed in 3 outcomes: deterioration, stability, or improvement. RESULTS: The overall 12-month-standardized mean change of the total score mean ± SD annual total score change was -2.4±5.5 points (P

Published
2012

50. Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population

Author

Nathanael Lapidus, Laurent Abel, Nicolas Salez, Pierre Le Cann, Pierre-Yves Boëlle, Nanikaly Moyen, Michaël Schwarzinger, Marianne Leruez-Ville, Simon Cauchemez, Xavier de Lamballerie, Eric Vivier, Pascal Ferrari, Laurent Andreoletti, Frédéric Vély, Fabrice Carrat, Antoine Flahault, Rosemary M. Delabre, Michèle Legeas, Marie-Lise Gougeon, Michel Setbon, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille (APHM), Emergence des Pathologies Virales (EPV), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Institut National de la Santé et de la Recherche Médicale (INSERM), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centro Ricerche Produzioni Animali (CRPA), Immunité Anti-virale, Biothérapie et Vaccins (IABV), Institut Pasteur [Paris] (IP), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infections à Vih, Réservoirs, Pharmacologie des Antirétroviraux et Prévention de la Transmission Mère Enfant, Université Paris Descartes - Paris 5 (UPD5), Laboratoire de Virologie, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Modélisation mathématique des maladies infectieuses, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Centre d'études et de recherche en informatique et communications (CEDRIC), Ecole Nationale Supérieure d'Informatique pour l'Industrie et l'Entreprise (ENSIIE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), This study was supported by the Institut de Microbiologie et Maladies Infectieuses (IMMI-AVIESAN), the Institut de Santé Publique (ISP-AVIESAN), theFrench Ministry of Health and Assistance Publique Hôpitaux de Paris – PHRC 2010#AOM10199, the French Ministry of research and the Institut de Recherche enSante Publique (IReSP – TGIR 2009, Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Epidémiologie des maladies infectieuses et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance Publique - Hôpitaux de Marseille ( APHM ), Emergence des Pathologies Virales ( EPV ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), École des Hautes Études en Santé Publique [EHESP] ( EHESP ), Centro Ricerche Produzioni Animali ( CRPA ), Immunité Anti-virale, Biothérapie et Vaccins ( IABV ), Centre d'Immunologie de Marseille - Luminy ( CIML ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ), Laboratoire de Virologie Médicale et Moléculaire ( CardioVir ), Université de Reims Champagne-Ardenne ( URCA ) -Centre Hospitalier Universitaire de Reims ( CHU Reims ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), CHU Saint-Antoine [APHP], Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Centre d'étude et de recherche en informatique et communications ( CEDRIC ), Ecole Nationale Supérieure d'Informatique pour l'Industrie et l'Entreprise ( ENSIIE ) -Conservatoire National des Arts et Métiers [CNAM] ( CNAM ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Infection, Antimicrobiens, Modélisation, Evolution ( IAME ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Unité de Santé Publique, Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE)-CHU Saint-Antoine [APHP], Epidémiologie, Systèmes dínformation et modélisation ( ESIM ), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Epidémiologie, Systèmes dínformation et modélisation (ESIM)

Subjects
Male, Viral Diseases, Epidemiology, [SDV]Life Sciences [q-bio], lcsh:Medicine, MESH : Child, Preschool, France/epidemiology, Influenza A Virus, H1N1 Subtype/*pathogenicity, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, MESH : Child, Risk Factors, MESH: Risk Factors, MESH: Child, Pandemic, Medicine, MESH : Female, 030212 general & internal medicine, MESH : Influenza, Human, lcsh:Science, Child, Epidemiological Methods, 0303 health sciences, education.field_of_study, Multidisciplinary, MESH : Pandemics, MESH: Middle Aged, MESH: Influenza, Human, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, Middle Aged, MESH : Risk Factors, MESH: Infant, 3. Good health, MESH : Influenza A Virus, H1N1 Subtype, Vaccination, Infectious Diseases, Influenza, Human/*epidemiology, MESH: Young Adult, Child, Preschool, Cohort, Female, France, Research Article, Adult, MESH: Pandemics, Adolescent, Clinical Research Design, MESH : Male, Population, Protective factor, MESH : Young Adult, Infectious Disease Epidemiology, MESH: Influenza A Virus, H1N1 Subtype, 03 medical and health sciences, Young Adult, MESH : Adolescent, Influenza, Human, Humans, MESH : Middle Aged, education, MESH : France, Biology, Pandemics, 030304 developmental biology, Asthma, MESH: Adolescent, MESH: Humans, [ SDV ] Life Sciences [q-bio], Population Biology, business.industry, MESH : Humans, lcsh:R, MESH: Child, Preschool, Infant, MESH: Adult, medicine.disease, Confidence interval, Influenza, MESH: Male, Risk perception, MESH: France, Cross-Sectional Studies, Immunology, lcsh:Q, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, Demography
Abstract

International audience; The CoPanFlu-France cohort of households was set up in 2009 to study the risk factors for infection by the pandemic influenza virus (H1N1pdm) in the French general population. The authors developed an integrative data-driven approach to identify individual, collective and environmental factors associated with the post-seasonal serological H1N1pdm geometric mean titer, and derived a nested case-control analysis to identify risk factors for infection during the first season. This analysis included 1377 subjects (601 households). The GMT for the general population was 47.1 (95% confidence interval (CI): 45.1, 49.2). According to a multivariable analysis, pandemic vaccination, seasonal vaccination in 2009, recent history of influenza-like illness, asthma, chronic obstructive pulmonary disease, social contacts at school and use of public transports by the local population were associated with a higher GMT, whereas history of smoking was associated with a lower GMT. Additionally, young age at inclusion and risk perception of exposure to the virus at work were identified as possible risk factors, whereas presence of an air humidifier in the living room was a possible protective factor. These findings will be interpreted in light of the longitudinal analyses of this ongoing cohort.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results